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Introduction 1 
 1. Introduction 
 
1.1. Alpha smooth muscle actin–positive cells in lung development: 
overview, appearance and function 
 
Murine lung development starts at embryonic day E9.5 (E9.5) with the formation of 
two buds, distal to the rudimentary trachea, on the ventral side of the primitive foregut 
endoderm. From E9.5 through E16, the epithelium undergoes a process of branching 
morphogenesis, which is regulated by epithelial/mesenchymal interactions and 
mechanical tension. As a result of this branching process, a tree-like tubular structure 
of the lung forms. At the same time as the lung branching process occurs, smooth 
muscle cells (SMCs) appear on the dorsal side of the trachea as well as around the 
bronchi and blood vessels through the differentiation of mesenchymal progenitor 
cells (Cardoso and Lu, 2006; Morrisey and Hogan, 2010). Distally, SMCs appear at 
the cleft site of the bud, prior to its branching, wrapping around the bifurcating bud. 
This process of smooth muscle cells wrapping the bifurcating bud, likely leading to 
the stabilization of the cleft, is very important since disruption of SMCs differentiation 
during this time leads to failure of branching (Kim et al., 2015). The appearance of 
smooth muscle cells around the bronchi begins several days before the appearance 
of smooth muscle cells around vessels (Li et al., 1996; McHugh, 1995). In the 
developing lung, SMCs defined as mesenchymal-derived ACTA2+ cells, can be 
initially subdivided into vascular SMCs (VSMCs) and airway SMCs (ASMCs). 
Through their supportive/structural as well as contractile properties, they contribute to 
the stabilization as well as the homeostasis of the vascular system and the 
conducting airways. Both cell types are therefore extremely important, allowing 
normal respiratory function at birth and impaired formation or function of SMCs lead 
generally to organ failure.  
The development of gas-exchange units called alveoli begins from E16.5 and 
continues after birth. Alveolarization includes thinning of the mesenchyme, 
enlargement of the distal airspaces and division by septation. Septation will result in 
formation of saccules containing a layer of double capillary network. The future 
alveoli are formed from saccules through the appearance of secondary septae that 
divides the saccules into airway sacs. The double capillary network inside the 
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alveolar walls remodel into a single-capillary layer. During the development of alveoli, 
the lung interstitium contains cells with smooth muscle cells characteristics. These 
cells are located at the tip of forming secondary septae and are called alveolar 
myofibroblasts (MYFs). During alveolarization alveolar MYFs express ACTA2 and 
form elongated cytoplasmic protrusions, establishing a continuous loop around the 
forming septal cup. These loops are interconnected to each other and form a 
“Fishnet”-like ACTA2+ network with strings of the fishnet underlying future alveolar 
ridges (Branchfield et al., 2016). Alveolar MYFs deposit elastin and play a critical role 
in alveoli formation (Dickie et al., 2008). Absence of alveolar MYFs leads to failure of 
secondary septation and alveoli formation (Boström et al., 1996). Schematic 
representation of alveolarization is illustrated in Figure 1. 
Thus, there are three types of alpha smooth muscle actin (ACTA2)–positive cells in 
the healthy lung: airway smooth muscle cell, vascular smooth muscle cell and 
alveolar myofibroblast. ASMCs and VSMCs are forming during early lung 
development, while alveolar MYFs are forming at late lung development, maturate 
postnatally and are not present in adult lung 
The origin of lung ASMCs and VSMCs as well as alveolar MYFs is progressively 
emerging. There is a need for better understanding of the origin of SMCs that will 
lead to improvement of potential treatments against diseases associated with SMCs 
overproliferation such as asthma, broncho-pulmonary dysplasia and pulmonary 
fibrosis. 
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Figure 1. Schematic representation of alveolarization and cell types involved.   
A. At the saccular stage of development, the lung forms primitive alveoli (saccule) 
surrounded by collagen fibers, nerves and blood vessels. B. The alveolar saccule is 
characterized by the presence of AECI/II, coating the walls of saccule, surfactant 
production, expansion of capillary tree, production of collagen and elastin by 
fibroblasts. C. During the alveolar stage, the sacs are subdivided by a process called 
“secondary septation”, which will give rise to mature alveoli. D. Secondary septae 
start to appear at the place of elastin deposition, which is produced by alveolar MYF. 
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The septae elongate toward the alveolar sac airspace. Double layer of capillaries 
become thinner giving rise to one layer of capillary network for more efficient gas 
exchange. AECI/II – alveolar epithelial cell type I/II; BADJ – broncho-alveolar duct 
junction; LIF – lipofibroblast; MYF – myofibroblast. Modified from Chao et al., 2016. 
 
1.1.1. Airway and vascular SMCs and their progenitors 
Several studies show that multiple progenitor cells participate to the smooth muscle 
cell pool during lung development. Mesenchymal progenitors expressing fibroblast 
growth factor 10 (Fgf10), Wilm’s tumor 1 (Wt1) or glioma-associated oncogene 1 
(Gli1) contribute to SMC formation from early stages of lung development. 
1.1.1.1. Fibroblast growth factor 10+ progenitors 
FGF10 is a key signaling pathway that is required for the branching process (Bellusci 
et al., 1997b; Sekine et al., 1999; Weaver et al., 2000). Fgf10 null mutation as well as 
expression of dominant negative FGF receptor completely prevent the branching 
process in mice (Peters et al., 1994; Sekine et al., 1999). Fgf10 is expressed in the 
distal lung mesenchyme during early lung development and acts via the Fibroblast 
growth factor receptor 2-IIIb (FGFR2b) on the adjacent epithelium to induce 
branching. The distal lung mesenchyme, expressing FGF10 stimulates the epithelial 
bud to grow into the distal mesenchyme (Bellusci et al., 1997b; Lü et al., 2005; Park 
et al., 1998). Apart from lung branching, FGF10 also plays role in ASMC 
development. Using Fgf10LacZ enhancer trap line, in which expression of LacZ 
recapitulates endogenous Fgf10 expression, we previously showed that Fgf10-
expressing progenitor cells during the early pseudoglandular stage massively 
contribute to the ASMC pool (Mailleux et al., 2005). However, our recent lineage 
tracing data using the Fgf10CreERT2 knock in line (El Agha et al., 2012) showed that 
only around 3-18% of the Fgf10-expressing cells labeled before E13.5 contribute to 
the SMCs (both vascular and airway). In addition, after E14.5, these progenitor cells 
are no longer committed to the SMC lineage (El Agha et al., 2014). The discrepancy 
between the two approaches (Fgf10LacZ versus Fgf10CreERT2) is still unresolved.  
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1.1.1.2. Mesothelial WT1+ progenitors 
The role of the mesoderm derived-mesothelium, a monolayer of flattened squamous-
like epithelial cells forming the external lining of the lung remains controversial. 
Mesothelial cells, positive for the Wilm's tumor marker 1 (WT1), were initially 
described as a source of VSMCs. Using the Wt1-Cre driver line, where a non-
inducible Cre is expressed under the control of the Wt1 promoter, it was proposed 
that WT1+ cells migrate and invade the mesenchyme of the developing lung, 
consequently giving rise to VSMCs, but not ASMCs (Que et al., 2008). Contrasting 
follow-up results were reported using the Wt1CreERT2 line (a better lineage-tracing tool) 
where it was shown that mesothelial cells do not significantly contribute to the VSMC 
lineage when labeled at E9.5 (Greif et al., 2012). A more recent study suggested that 
mesothelial cells, labeled at E10.5 and E11.5, contribute to ASMCs and VSMCs, as 
well as DESMIN+ fibroblasts (Dixit et al., 2013). Beyond the difference in the time of 
labeling, the extent of the mesothelium's contribution to the SMC lineage is so far 
unclear. 
1.1.1.3. Sonic hedgehog-responding GLI1+ progenitors 
Sonic hedgehog (SHH) signaling has been also known as a key regulator of lung 
epithelial branching and ASMC development (Bellusci et al., 1997b). SHH signaling 
is activated by the binding of SHH ligand to the receptor Patched (PTC), which stops 
PTC-mediated inhibition of Smoothend (SMO) protein. Relieved SMO induces GLI-
proteins to translocate to the nucleus and bind to SHH-responsive elements 
(McMahon, 2000). Upregulation of glioma-associated oncogene 1 (Gli1), a main 
transcription factor operating downstream of SHH (Bai et al., 2004; Grindley et al., 
1997; Hynes et al., 1997; Lee et al., 1997; Méthot and Basler, 2001; Miller et al., 
2004) but likely also downstream of other signaling pathways such as FGF9 (del 
Moral et al., 2006), appears to be important for the differentiation of mesothelial cells 
along the SMC lineage (Dixit et al., 2013). This is in line with the phenotype of Shh 
knock out lungs showing complete absence of SMC (Miller et al., 2004; Pepicelli et 
al., 1998). Using the Gli1CreERT2 driver line, it was shown that E10.5 GLI1+ cells and 
their descendants give rise to ASMCs and VSMCs as well as other parenchymal 
cells at E18.5 (Li et al., 2015). For this reason, it was proposed that the Gli1CreERT2 
driver line could be useful to target the SMC lineage with a certain level of specificity. 
Using the same driver line, a multipotent population of cardio-pulmonary progenitors 
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(CPPs), which are marked by the expression of Gli1 as well as Wnt2 and Isl1, was 
identified. GLI1+ CPPs, labeled at E8.5, give rise to different mesenchymal lineages, 
including pulmonary ASMCs and VSMCs. CPPs are regulated by SHH that is 
expressed by the foregut endoderm (Peng et al., 2013). The above-mentioned 
ASMCs progenitors are summarized in figure 2.  
 
 
 
Figure 2. Airway smooth muscle cell progenitors. WNT2+, GLI1+ and ISLl1+ 
cardio-pulmonary progenitors labeled at E8.5 give rise to proximal ASMC. Distally 
ASMCs are coming from mesothelial WT1+ cells and FGF10+ cells (both initially 
ACTA2-). 
  
1.1.1.4. Progenitors with active WNT signaling 
The WNT family consists of 19 secreted WNT ligands interacting with 10 Frizzled 
(FZD) receptors and 2 low-density lipoprotein related protein receptors LRP5 and 
LRP6. WNT signaling is divided into canonical and non-canonical pathway. The 
canonical pathway includes Wnt ligand binding to FZD receptor that leads to 
hypophosphorilation of β-catenin, translocation of β-catenin to nucleus and activation 
of lymphoid enhancer binding factor/t-cell factor (LEF/TCF) transcription factors to 
induce target gene expression. The non-canonical pathway includes activation of c-
Jun kinase (JNK) (Wang et al., 2005). Mice expressing β-galactosidase under the 
control of a LEF/TCF and β-catenin inducible promoter showed that in the E10.5 and 
E12.5 lung WNT signaling is active in airway epithelium and ASMCs. After E13.5 β-
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galactosidase activity is absent in mesenchyme and is reduced in epithelium, 
correlating with the onset of Dickkopf-1 (Dkk1) expression, a gene encoding an 
inhibitor of WNT signaling. It was shown that lung explants treated with DKK1 display 
impaired branching and reduced ASMC and VSMC formation (De Langhe et al., 
2005). This suggests that WNT signaling may be involved in SMCs formation. It was 
also shown that WNT/β-catenin signaling in mesenchyme is crucial for the 
amplification but not differentiation of Fgf10-expressing cells that give rise to SMCs 
(De Langhe et al., 2008). Some of the WNT ligands have been also shown to play a 
role in pulmonary SMCs development. For example loss of Wnt7b resulted in loss of 
VSMCs integrity and lung hypoplasia (Shu et al., 2002). WNT7b ligand is secreted by 
epithelium and acts via FZD1 receptor on the mesenchyme, including VSMCs (Wang 
et al., 2005). Another WNT ligand seems to be important for lung SMCs formation – 
WNT2. As it was described before, cardio-pulmonary progenitors that give rise to 
ASMCs and VSMCs express Wnt2 (Peng et al., 2013). It was also shown that 
specific inactivation of β-catenin (Ctnnb1) in SMCs using the SM22-Cre driver line 
leads to decreased ASMC and VSMC formation in the lung (Cohen et al., 2009). This 
study again underscores the importance of WNT signaling in seemingly differentiated 
SMCs and/or their intermediate SM22+ progenitors for SMC formation. The role of 
WNT signaling in SMCs formation remains unclear. There is a need for lineage-
tracing studies to monitor cells with active WNT signaling. 
1.1.1.5. Progenitors coming from pre-existing ACTA2+ cells 
It remains unclear whether differentiated SMCs serve as progenitors for newly 
forming SMCs, particularly due to their limited proliferation capacity during 
developmental stages (El Agha et al., 2014). 
It has been proposed that SMC progenitors are located proximally, near the lung 
hilum. This is the site found on the medial part of each lung, where the bronchi, blood 
vessels and nerves enter and exit the lung. These progenitor cells are believed to 
expand towards the distal/peripheral part of the lung, while giving rise to ASMCs 
(Shan et al., 2008). A more recent study has shown that pulmonary arterial SMCs 
(PASMCs) derive from progenitor cells located in the mesenchyme immediately 
surrounding the arteries at E13.5 (Greif et al., 2012). It was shown that PASMCs 
proliferate, migrate radially and give rise to the outer SMC layer. A more recent study 
showed that under hypoxic conditions, most distal PASMCs derive from pre-existing 
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SMCs in the adult lung. These pre-existing distal SMCs dedifferentiate, migrate more 
distally, proliferate and re-differentiate to new SMCs (Sheikh et al., 2014).  However, 
this does not apply to ASMC formation, as it appears that the mesenchyme located 
immediately close to bronchi (stalk mesenchyme) does not contribute to ASMCs, at 
least not at E13.5. ASMC progenitors are proposed to be located exclusively at the 
tips of the budding bronchi, and migration of these progenitors to the site of 
differentiation seems to be WNT-dependent (Kumar et al., 2014; Mailleux et al., 
2005). 
1.1.2. Alveolar myofibroblasts and their progenitors 
Alveolar myofibroblasts (MYFs) are ACTA2+ mesenchymal cells that transiently 
populate the lung during the alveolar stage of lung development. During lung 
development, alveolar MYFs are believed to be present mostly in a progenitor state 
(based on low levels or even absence of Acta2 expression in the lung parenchyma). 
Alveolar MYFs are believed to be critical for the formation of secondary septa during 
alveologenesis, thereby allowing the subdivision of the respiratory saccules into 
smaller units, the alveoli.  
Apart from the expression of ACTA2, alveolar MYFs are producing extracellular 
matrix fibers, such as elastin and collagen. Elastin deposition is critical for the normal 
alveoli, maintaining the alveolar integrity and allowing alveoli to stretch during 
inhalation (Dickie et al., 2008). During alveolarization, elastin forms a matrix that 
serves as a scaffold on which alveolar MYFs adhere and mark future secondary 
septae sites. In Elastin-knock-out lungs, secondary septae failed to form and lungs 
exhibited an emphysematous-like phenotype. Mutant mice die within a few days after 
birth before alveologenesis began (Wendel et al., 2000). 
Alveolar MYFs are abundant in the postnatal lung but they disappear after 
alveolarization process and are absent in adult lung (Kapanci et al., 1995; Yamada et 
al., 2005). Dysregulated behavior of MYFs are involved in several lung diseases such 
as fibrosis and BPD thus disappearance of alveolar MYFs from the lung is important, 
since they might be involved in disease process. The disappearance of alveolar 
MYFs from the lung is poorly understood and requires further investigation.  
The origin of alveolar MYFs is still not understood. The use of specific driver lines 
directly targeting alveolar MYF progenitors is needed to follow the fate of these cells 
postnatally, as well as during repair after injury. 
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1.1.2.1. PDGFA signaling in alveolar MYF formation 
It was proposed that alveolar MYFs are derived from platelet derived growth factor 
receptor alpha+ (PDGFRa+) cells. At the end of the saccular stage and at the 
beginning of secondary septae formation (PN0-PN3) PDGFRa+ cells migrate to 
future sites of septae formation. PDGFA-mediated activation of PDGFRA is neded for 
proliferation and spreading of alveolar MYF progenitors (Lindahl et al., 1997). In 
newborn Pdgfa-null mice, this migration is absent and lungs display complete 
absence of alveolar MYFs and elastin deposition as well as failure of alveolar 
septation (Boström et al., 1996; Lindahl et al., 1997; McGowan et al., 2008). 
Interestingly, Pdgfra mutants did not show any failure of alveolar MYFs migration 
(Boström et al., 2002; McGowan and McCoy, 2014, 2013a). More recent study 
proposed that PDGFRa+ cells give rise to alveloar MYFs and later differentiate into 
lipofibroblasts (LIF) (Branchfield et al., 2016). Altogether these data suggest that 
alveolar MYFs undergo PDGFA/PDGFRa signaling (Boström et al., 1996; Lindahl et 
al., 1997; McGowan et al., 2008), but the exact role of this signaling pathway, in 
terms of proliferation and/or differentiation, remains unclear. To demonstrate that 
PDGFRa+ cells present at pseudoglandular stage are indeed progenitors for alveolar 
MYF lineage tracing experiments of PDGFRa+ cells must be performed.  
1.1.2.2. FGF signaling in alveolar MYF formation 
FGF signaling has also been shown to play an important role in alveolar MYF 
formation. Lungs of the Fgf10 hypomorph mice, expressing around 20% of normal 
Fgf10 expression, display complete absence of alveolar MYFs and respiratory 
airways are significantly enlarged (Ramasamy et al., 2007). Inhibition of all FGFR2b 
ligands, including FGF10, by using dominant negative approach overexpressing 
soluble form of FGFR2b (Spc-rtTA/+; tet(O)solFgfr2b/+) during lung development 
(E14.5-E18.5) led to disrupted alveologenesis. Treatment with retinoic acid (RA), a 
vitamin A derivative, can partially restore the process – secondary septa will form 
with presence of alveolar MYFs. But this regenerative effect of RA can be blocked by 
re-expression of sFGFR2b, suggesting that FGFR2b ligands are critical for 
secondary septa formation not only during development but also postnatally (Perl 
and Gale, 2009). Another study showed that FGFR2b ligands are important during 
alveolar regeneration process after pneumonectomy (Chen et al., 2012). The same 
study proposed that PDGFRa+ LIFs give rise to alveolar MYFs and this process 
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involves FGFR2b ligands (likely FGF10). Clearly FGFR2b ligands (particularly 
FGF10) are involved in alveolar MYF formation, but it is still unclear whether this 
effect is direct effect of FGF10 on alveolar MYF progenitors or indirect effect via 
alveolar epithelial type II cells (AECII), while AECII are the major epithelial 
component of forming alveoli. Interestingly, forced activation of FGF in lung 
mesenchyme during lung development also led to absence of alveolar MYFs and 
reduced elastin expression (De Langhe et al., 2006). This result suggests that FGF10 
might act in different ways – it might prevent alveolar MYF differentiation allowing 
their proliferation or induce alveolar MYF differentiation. These different effects of 
FGF10 might be possible when FGF10 acts via different receptors – either via 
FGFR2b or FGFR2c.   
1.1.2.3. SHH and WNT signaling in alveolar MYF formation 
It has been demonstrated that migration of alveolar MYFs to the sites of secondary 
septation is dependent on SHH signaling (McGowan and McCoy, 2013b). 
Downstream target of SHH signaling GLI1 that has been shown to be involved in 
ASMC and VSMC formation is also involved in alveolar MYF formation. Using 
Gli1CreERT2 driver line to specifically target cells undergoing SHH signaling it was 
shown that GLI1+ cells labeled at E10.5 give rise to alveolar MYFs at PN14 and this 
process depends on WNT signaling. Ectopic activation of WNT signaling by targeted 
inactivation of Adenomatosis polyposis coli (Apc) led to significant increase in 
alveolar MYFs which subsequently led to formation of multiple fibrotic masses in the 
perinatal lungs (Li et al., 2015). 
 
1.2. Smooth muscle cells in lung disease 
 
Abnormal behavior of ACTA2+ cells is known to be involved in numerous pathological 
conditions such as asthma, pulmonary hypertension (PH), broncho-pulmonary 
dysplasia (BPD) and fibrosis. ASMCs in the lungs of asthmatic patients have features 
of hyperplasia and hypertrophy, airways are hyper responsive and the airflow is 
reduced (Halayko and Stephens, 1994; Jeffery, 2004). Pulmonary hypertension is 
associated with excessive VSMC proliferation, which involves alteration in all three 
layers (intima, media and adventitia) of the vascular wall, often with the interplay of 
inflammatory cells (Tuder, 2016). BPD is a lung disease of prematurely born infants 
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that are being treated with mechanical ventilation. Among the features of BPD is 
overproliferation of ASMCs (Bland, 2005). Some of lung diseases such as pulmonary 
fibrosis and BPD are characterized by the presence of another ACTA2+ cell type – 
the activated MYF. In pulmonary fibrosis overproliferation of activated MYFs result in 
scarring of lung tissue, deposition of collagen and extracellular matrix (Thannickal et 
al., 2004; Zhang et al., 1996). The origin of the over-proliferative SMCs and MYFs in 
pathological conditions is very poorly understood. There is a great need to expand 
this knowledge. Additionally, SMCs by themselves serve as an important 
intermediate source of signaling molecules during the repair process in different 
diseases. For example, it was shown that ASMCs secret FGF10 to induce repair 
process after naphthalene-induced epithelial injury in mice (an established model to 
deplete airway epithelial Clara cells or Club cells) (Volckaert et al., 2011). 
Understanding the role and impact of SMCs on repair process is another interesting 
issue that needs to be investigated. 
1.2.1. Smooth muscle cells and activated myofibroblasts in bleomycin-induced 
lung fibrosis 
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by scarring of 
lung tissue and progressive decline in lung function. One of the primary effector cells 
in IPF lungs are ACTA2+ activated MYFs, cells that are responsible for extracellular 
matrix production (ECM) such as collagen and leading to scarring of the tissue. 
Progressive scarring prevents gas exchange, ultimately leading to respiratory failure 
and death.  
The pathogenesis and treatment of IPF, however, remains unclear (du Bois et al., 
2011). It has been speculated that repetitive injury to alveolar type II cells (AECII) 
may be the prime event that initiates mesenchymal cells recruitment and ECM 
deposition (Günther et al., 2012). Injury to alveolar epithelial cells will lead to the 
emergence of spindle-shaped fibroblasts located in fibrotic foci. These foci will be the 
sites of activated MYF accumulation and tissue remodeling. Additionally, misfolding 
of surfactant proteins A and C (SFTPA and C) leads to endoplasmic reticulum stress 
and reactive oxygen species production by AECII, which contributes to lung 
remodeling. TGFβ pathway, particularly TGFβ1 is believed to drive the fibrotic 
response in IPF lungs. It has been shown that TGF-β1 Requires SMO/GLI Pathway 
activity to trigger and sustain MYF differentiation. Inhibition of GLI partially reverts 
MYF phenotype (Cigna et al., 2012). Another study shows that GLI1+ cells proliferate 
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after kidney, lung, liver, or heart injury to generate MYFs (Kramann et al., 2015). 
The cellular origin of activated MYFs in IPF has been a topic of high interest but still 
remains understudied. There are several hypotheses suggesting some cell types that 
can give rise to activated MYFs. It has been proposed that activated MYFs originate 
from resident fibroblasts expressing high affinity type II TGFb receptor. These 
resident fibroblasts proliferate and start to express ACTA2 (Hoyles et al., 2011). 
Another hypothesis is that activated MYFs originate from circulating bone-marrow-
derived fibrocytes (Hashimoto et al., 2004; Phillips et al., 2004). Pericytes, ACTA2+ 
contractile cells that wrap around the endothelial cells of capillaries and venules, 
were also suggested as a source for activated MYFs in lung fibrosis (Hung et al., 
2013; Rock et al., 2011; Wong et al., 2015). Additionally, many studies suggest that 
activated MYFs derive from epithelial cells of the lung, including AECII, undergoing 
TGFβ1-driven epithelial-mesenchymal transition (EMT) (Corvol et al., 2009; Degryse 
et al., 2010; Felton et al., 2009; Tanjore et al., 2011; Willis et al., 2006). However, 
there was no evidence for EMT when AECII were lineage-traced during bleomycin-
induced lung fibrosis (Rock et al., 2011). The potential cell types giving rise to 
activated MYFs are illustrated in Figure 3. It is still unclear whether pre-existing 
ACTA2+ airway and vascular SMCs can give rise to activated MYFs in lung fibrosis. 
It is widely accepted that the pathogenesis of IPF starts in the alveolar region of the 
lung. Alveolar region of the lung harbors lipid droplet-containing cells – lipofibroblasts 
(LIFs) that are located in close proximity to AECII. LIF are involved in alveolar 
maturation and surfactant production (Rehan and Torday, 2014) and contribute to the 
epithelial stem-cell niche in adult mouse lungs (Barkauskas et al., 2013; McQualter et 
al., 2013). Our group has shown that LIFs trace back to at least one embryonic 
mesenchymal cell population expressing Fgf10 (El Agha et al., 2014). The 
involvement of LIFs in alveolar repair after injury has not been investigated.  
An in-vivo bleomycin-induced model for IPF in mice is commonly used (Degryse and 
Lawson, 2011). In this model, the anti-cancer drug bleomycin is administered 
intratracheally or systemically which leads to the development of fibrotic lesions. In 
contrast to IPF in humans, where fibrosis induces irreversible pathological 
remodeling, bleomycin-induced fibrosis in mice is followed by repair with complete 
recovery. After fibrosis resolution activated MYFs have been thought to undergo 
apoptosis (Hinz et al., 2007; Issa et al., 2001). Recent data indicate that during 
fibrosis resolution activated MYFs dedifferentiate and this dedifferentiation is 
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controlled by ERK and MAPK pathways. In contrast, during fibrosis onset, 
myofibroblast formation is driven by TGFb1, MyoD and ALK5 (Hecker et al., 2011). 
This study hypothesized that activated MYF descendants dedifferentiate to LIFs that 
are associated with alveolar repair. 
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Figure 3. Putative cell types giving rise to activated myofibroblasts. Resident 
fibroblast/lipofibroblast, AECII, pericytes and circulating fibrocytes are potential 
precursor cells giving rise to activated MYFs. It remains unknown whether ASMC and 
VSMC can give rise to activated MYFs. AECI/II – alveolar epithelial type I/II cells, 
EMT – epithelial-mesenchymal transition.  
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2. Objectives 
 
The lung mesenchyme, in comparison to the lung epithelium remains understudied. 
Among the mesenchymal cells that are poorly characterized are airway and vascular 
SMCs in addition to alveolar MYFs. Although conventional SMCs and alveolar MYFs 
share ACTA2 expression, little is known about the differences in terms of cellular 
origin and gene expression between these cell types. ACTA2+ cells play crucial roles 
during development to establish mature lungs and also during the repair process 
after injury. More detailed understanding of the origin and fate of SMCs and alveolar 
MYFs during development and repair will definitely bring new ideas for the potential 
treatments against proliferative diseases such as asthma, BPD, PH and pulmonary 
fibrosis. 
This study provides a more balanced view on the origin, fate and role of ACTA2+ 
cells during embryonic lung development and lung regeneration. In vivo lineage 
tracing followed by fluorescence-activated cell sorting, gene expression analysis and 
histological examination were used to address our scientific questions. Our side-by-
side analyses will be instrumental to design new experiments addressing the function 
of signaling pathways in various ACTA2-derived subpopulations. 
This study is divided into two parts, emphasizing the following topics: 
1. The origin of SMCs and alveolar MYFs during murine lung development. 
Using in vivo lineage tracing of different mesenchymal progenitors that were 
reported to target SMCs the impact of different progenitor cells to SMCs and 
alveolar MYFs was measured. The driver lines used for this study included 
Fgf10CreERT2 to target FGF10+ cells, Wt1CreERT2 to target mesothelial cells, 
Gli1CreERT2 to target SHH-responding cells, Axin2CreERT2 to target cells with 
activated WNT signaling and Acta2-CreERT2 to target differentiated SMCs. 
Tomatoflox line was used to label cells with tdTomato signal. Specific cell 
populations were labeled at different time points of development and were 
lineage-traced and analyzed at later time points.  
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2. The origin and fate of activated MYFs in bleomycin-induced lung fibrosis 
in mice 
One of the proposed origin for the activated MYFs are pre-existing ACTA2+ 
cells (Sheikh et al., 2014). Using the Acta2-CreERT2; Tomatoflox line we tested 
the hypothesis whether pre-existing ASMCs and VSMCs give rise to activated 
MYFs. For that reason ACTA2+ SMCs were labeled before bleomycin injury to 
induce lung fibrosis.  At the peak of fibrosis the presence of labeled ACTA2+ 
cells was measured. To study the fate of activated MYFs, the same Acta2-
CreERT2; Tomatoflox line was used. ACTA2+ activated MYFs were labeled 
during the fibrotic phase and the fate of these cells were studied, particularly 
whether these activated MYFs persist in the lung and transition to a 
lipofibroblast-like phenotype during fibrosis resolution. 
 
The objectives of this study are summarized below: 
 
1. Identifying the relative contribution of various mesenchymal progenitors to 
airway and vascular SMC formation during embryonic lung development 
2. Identifying alveolar MYF progenitors during late lung development 
3. Establishing transcriptomic signatures for various ACTA2+ cell populations 
during late lung development 
4. Investigating the contribution of pre-existing SMCs to activated MYFs in lung 
fibrosis postnatally 
5. Targeting activated MYFs during fibrosis formation and tracing their fate 
during the resolution phase in adult mice 
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3. Materials and Methods 
 
3.1. Mice and animal experiment approval 
 
The Fgf10-LacZ (Fgf10Tg(Mlc1v-nLacZ)) mouse line was described previously (Kelly et al., 
2001; Mailleux et al., 2005). Fgf10CreERT2 (B6-Fgf10tm1.1(cre/ERT2)Sbel) mice were 
generated previously by our group (El Agha et al., 2012). Mouse strains Axin2LacZ 
(B6.129P2-Axin2tm1Wbm/J, stock number 009120), Gli1LacZ (STOCK_Gli1tm2Alj/J, stock 
number 008211), Wt1CreERT2 (STOCK_Wt1tm2(cre/ERT2)Wtp/J, stock number 010912), 
Gli1CreERT2 (STOCK_Gli1tm3(cre/ERT2)Alj, stock number 007913), Axin2CreERT2 
(B6.129(Cg)-Axin2tm1(cre/ERT2)Rnu/J, stock number 018867) and tdTomatoflox 
(B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J, stock number 007905) were 
purchased from Jackson laboratory. Acta2-CreERT2 (STOCK_Tg(Acta2-
cre/ERT2)12Pcn) mice (Wendling et al., 2009) were kindly provided by Dr. Pierre 
Chambon. 
Animal experiments were approved by Regierungspraesidium Giessen (117/2012, 
55/2015 and 613_M). 
3.2. Mice Genotyping  
Tissues from the distal tip of the tails were digested in 200 l Viagen including 1 l 
proteinase K in 55°C on a shaker overnight, then reaction was stopped in 85°C for 40 
min. Genotyping were done by PCR. For protocol and primer sequences please see 
Table 1. PCR products were analyzed using a 1,5 % agarose gel containing TAE 
buffer with Sybrsafe (50 l Sybrsafe + 500 ml 1x TAE buffer). 10 l of PCR samples 
were loaded with 2 l loading dye (Biorad Nucleic Acid Sample loading buffer, 5x), 
and then gel was run with 120V for 30-45 min. A molecular ladder (QX Size Marker, 
100bp-2.5kb, Qiagen) was used to detect the expected band sizes (Table 2). 
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Table 1. Primer sequences and protocols for genotyping. 
Mouse line Primer sequence  PCR protocol 
Step Temp. 
(°C) 
Time 
Fgf10-LacZ Run separately LacZ/WT: 
1) LacZ: TTC ACT GGC CGT CGT 
TTT ACA ACG TCG TGA  
2) LacZ: ATG TGA GCG AGT AAC 
AAC CCG TCG GAT TCT  
3) WT: CGA GTG GAG CAT GTA 
CTT CCG TGT CCT GAA 
4) WT: TCC CTA CCC AGT CAC 
AGT CAC AGC TGC ATA 
 
1 94 1/2 min  
2 94 30 sec 
3 55/59.5  30 sec 
4 (repeat 
Step 2-4 
31 times 
total) 
72 1 min 
5 72 5 min 
6 4 Hold 
Fgf10CreERT2 1) ATT TGC CTG CAT TAC CGG 
TC 
2) ATC AAC GTT TTG TTT TCG 
GA 
1 94 3 min 
2 94 30 sec 
3 51.7 1 min 
4 (repeat 
Step 2-4 
35 times 
total) 
72 1 min 
5 72 2 min 
6 4 Hold 
Axin2LacZ 1) AAG CTG CGT CGG ATA CTT 
GAG A 
2) AGT CCA TCT TCA TTC CGC 
CTA GC 
 
3) WT: TGG TAA TGC TGC AGT 
GGC TTG 
 
1 94 3 min 
2 94 30 sec 
3 67 30 sec 
4 (repeat 
Step 2-4 
35 times 
total) 
72 30 sec 
5 72 2 min 
6 4 Hold 
Gli1LacZ 1) GGG ATC TGT GCC TGA AAC 
TG 
2) TCT GCC AGT TTG AGG GGA 
1 94 3 min 
2 94 30 sec 
3 65 1 min 
4 (repeat 72 45 sec 
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Mouse line Primer sequence  PCR protocol 
Step Temp. 
(°C) 
Time 
CGA C 
3) WT: AGG TGA GAC GAC TGC 
CAA GT 
Step 2-4 
35 times 
total) 
5 72 2 min 
6 10 Hold 
Wt1CreERT2 Run separately Cre/WT: 
1) Cre: TGA AAC AGG GGC AAT 
GGT GCG 
2) Cre: CGG AAT AGA GTA TGG 
GGG GCT CAG 
3) WT: GCG ATC CTG GAC TTC 
CTC CT 
 
4) WT: GGA CCG CCC AGC GAC 
CCG TA 
1 94 3 min 
2 94 30 sec 
3 65/61  45 sec 
4 (repeat 
Step 2-4 
30/35 
times total) 
72 45 sec 
5 72 2 min 
6 10 Hold 
Gli1CreERT2 1) GGG ATC TGT GCC TGA AAC 
TG 
2) CTT GTG GTG GAG TCA TTG 
GA 
3) WT: CAG GTT CTT GCG AAC 
CTC AT 
1 94 5 min 
2 94 30 sec 
3  64.6 1 min 
4 (repeat 
Step 2-4 
35 times 
total) 
72 1 min 
5 10 Hold 
Axin2CreERT2 1) AAA GCT GCG TCG GAT ACT 
TG 
2) ACA TGT CCA TCA GGT TCT 
TGC 
3) WT: CTT GCC CAC ACT AGG 
CTG AC 
1 94 2 min 
2 94 20 sec 
3 65 15 sec 
4 (repeat 
Step 2-4 
11 times 
total) 
68 10 sec 
5 94 15 sec 
6 60 15 sec 
7 (repeat 
Step 5-7 
29 times 
total) 
72 10 sec 
8 72 1 min 
9 4 Hold 
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Mouse line Primer sequence  PCR protocol 
Step Temp. 
(°C) 
Time 
Acta2-
CreERT2 
1) ATT TGC CTG CAT TAC CGG 
TC 
2) ATC AAC GTT TTG TTT TCG 
GA 
1 94 30 sec 
2 94 30 sec 
3 55 30 sec 
4 (repeat 
Step 2-4 
30 times 
total) 
72 1 min 
5 4 Hold 
tdTomatoflox 1) CTG TTC CTG TAC GGC ATG 
G 
2) GGC ATT AAA GCA GCG TAT 
CC 
3) CCG AAA ATC TGT GGG AAG 
TC 
4) AAG GGA GCT GCA GTG GAG 
TA 
1 94 3 min 
2 94 20 sec 
3 61 30 sec 
4 (repeat 
Step 2-4 
35 times 
total) 
72 30 sec 
5 72 2 min 
6 4 Hold 
 
Table 2. Expected band size of genotyping products. 
Mouse line Expected band size 
for WT 
Expected band size 
for mutant 
Fgf10Lacz/-  500bp 370bp 
Fgf10CreERT2 - 349bp 
Axin2LacZ 493 bp 400 bp 
Gli1LacZ 261 bp 480 bp 
Wt1CreERT2 374 bp 194 bp 
Gli1CreERT2 136 bp 204 bp 
Axin2CreERT2 493 bp 520 bp 
Acta2-CreERT2 - 349bp 
tdTomatoflox 297 bp 196 bp 
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3.3. Tamoxifen administration 
 
Tamoxifen stock solution was prepared by dissolving tamoxifen powder (T5648, 
Sigma) in corn oil at a concentration of 20 mg/mL. Pregnant mice received a single 
intraperitoneal (IP) injection of 0.1 mg of tamoxifen per gram of body weight. For 
continuous tamoxifen exposure, mice were fed tamoxifen-containing food (0.4 g of 
tamoxifen per kg of food) (Altromin). 
3.4. Bleomycin injury 
 
Acta2-CreERT2, tdTomatoflox mice received an intratracheal installation of either 
saline or bleomycin (3.5 U/kg of body weight) at the Ludwig Boltzmann Institute in 
Graz, Austria (protocol number BMWFW-66.010/0043-WF/V/3b/2016) and National 
Jewish Health (Denver, USA) according to recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institute of Health (IACUC 
number AS2774-05-16). 
3.5. Lung function measurements 
 
Mice were anesthetized with Ketamine (1.2 l/g), Domitor (0.6 l/g) and 1:4 parts of 
Heparin (Ratiopharm) mixed in saline solution. Then mice were tracheotomized and 
intubated with a 20G catheter connected to a FlexiVentTM plesythmograph (Scireq). 
Lungs were mechanically ventilated at a rate of 150 breaths/min with a tidal volume 
of 10 l/g of body weight. Lung compliance was measured. After plesythmography, 
animals were euthanized and lungs were isolated for further processing. 
3.6. Fluorescence microscopy and time-lapse microscopy 
 
Dissected lungs were examined using a fluorescent stereoscope M205FA (Leica) 
equipped with DFC360FX camera (Leica). For time-lapse microscopy, E12.5 lungs 
were cultured on Whatman Nucleopore membrane filters (GE Healthcare) placed on 
500 μl of Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin. Culture dishes with embryonic lungs were 
placed in the chamber (37°C, 5% CO2) of the live imaging microscope DMI6000B 
(Leica) with DFC365FX camera (Leica), where live imaging was performed. 
For thick vibratome sections Z-stack and de-convolution was used. 
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3.7. Immunofluorescence and immunohistochemistry 
 
Isolated lungs were fixed with 4% paraformaldehyde (postnatal lungs were perfused 
with PBS prior to fixation, embryonic lungs were not perfused). Then, tissues were 
embedded in paraffin and sectioned at 5 μm thickness. Slides were deparaffinized 
and then blocked with 3% BSA and 0.4% Triton-X (in TBS) at RT for 1 h. If antigen 
retrieval was necessary it was performed prior blocking by placing slides in a staining 
container and steaming in a pressure cooker with 10mM citrate buffer, 0.05% Tween 
20, pH 6 for 15 min following 30 min cooling on ice and washing three times in TBST 
(TBS buffer + 0.1% Tween20) for 5 min. Then, slides were incubated with primary 
antibodies at RT for 1 h or at 4°C overnight. After incubation with antibodies, slides 
were washed three times in TBST for 5 min and stained with secondary antibodies at 
RT for 1 h. Slides were then washed three times in TBST for 5 min and mounted with 
Prolong Gold Anti-fade Reagent with DAPI (Invitrogen). Immunofluorescent (IF) 
stainings were performed using monoclonal anti-ACTA2 (Sigma, 1:200), polyclonal 
anti-ADRP (PLIN2) (Abcam, 1:50), monoclonal anti-Elastin (ELN) antibodies (Santa 
Cruz Biotechnology, 1:200), polyclonal anti-SFTPC (Santa Cruz, 1/1000), polyclonal 
anti-beta Galactosidase (β-gal) (Abcam, 1:200), polyclonal anti-collagen type 1 
(Rockland Immunochemicals, 1:200) and monoclonal anti-Ki67 (Cell Signaling, 
1:200). The endogenous tdTomato signal was detected without the use of antibodies. 
When antigen retrieval was required for double staining, polyclonal anti-tdTomato 
(anti-RFP) antibodies (Rockland Immunochemicals, 1:250) were used. Apoptosis 
was detected using DeadEnd Fluorometric TUNEL assay according to 
manufacturer’s instructions (Promega). For quantitative analysis, multiple images 
were used (n > 8). For each experiment, sections from at least 3 independent lungs 
were analyzed.  
Hematoxylin/Eosin staining was performed according to standard procedures. 
To get thick sections isolated lungs were filled with 1.5% low melting agarose 
(Invitrogen) and then vibratome sections were cut at 100 μm. After cutting lungs were 
kept overnight in PBS to get rid of agarose and then fixed in 4% paraformaldehyde 
and stained with antibodies.  
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3.8. X-Gal staining 
 
X-Gal staining of Fgf10-LacZ and Gli1-LacZ lungs was performed as previously 
described (Volckaert et al., 2011). Briefly, lungs were dissected in Hank’s Balanced 
Solution (HBSS) (Invitrogen), shortly fixed in 4% Paraformaldehyde (PFA), washed in 
PBS and incubated with LacZ buffer solution for 10 min. Then, they were incubated 
with LacZ buffer solution containing 40 mg/mL X-Gal at 37°C overnight. 
 
3.9. Flow cytometry analysis and cell sorting 
 
Individual embryonic lungs at E18.5 were isolated in Hank’s balanced salt solution 
(HBSS), cut into small pieces with a sharp blade and treated with 0.5% Collagenase 
Type IV in HBSS (Life technologies, Invitrogen) at 37°C for 45 minutes. Lung 
homogenates were passed through 18, 21 and 24G needles and then through 70 
and 40 μm cell strainers (BD Biosciences) to obtain single cell suspensions. Cells 
were centrifuged at 4°C at 1200 rpm for 5 minutes and then resuspended in staining 
solution (0,1% sodium azide, 5% FCS, 0,05% Triton X-100 in PBS) containing anti-
ACTA2 (FITC-conjugated, Sigma, 1:100) and anti-PDGFRa antibodies (APC-
conjugated, Biolegend, 1:100) for 30 minutes on ice in the dark. Then, cells were 
washed with 0.1 % sodium azide in PBS. LipidTOX staining was performed 
according to manufacturer’s protocol (Invitrogen). Flow cytometry measurements of 
labeled cells and cell sorting were done using a FACSAriaIII cell sorter (BD 
Biosciences). 
3.10. Quantitative Real-time PCR 
 
Extraction of RNA from sorted cells was performed using RNeasy Micro kit (Qiagen). 
Primers were designed using the Universal Probe Library Assay Design center 
program available online (Roche Applied Science). More details about the used 
primers can be found in table 3. Quantitative real-time PCR was performed using 
Light Cycler 480 II (Roche Applied Science). Data were obtained using 
hypoxanthine-guanine phosphoribosyltransferase (Hprt) as a reference gene. Data 
were presented as expression relative to Hprt.  
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Table 3. Mouse primers used for qPCR  
Gene Forward Primer 5’-3’ Reverse Primer 5’-3’ 
Adrp cctcagctctcctgttaggc cactactgctgctgccattt 
Acta2 actctcttccagccatctttca ataggtggtttcgtggatgc 
Elastin ccacctctttgtgtttcgct ccaaagagcacaccaacaatca 
Fgf10 atgactgttgacatcagactcctt cactgttcagccttttgagga 
HPRT gctgacctggattac ttggggctgtactgctta 
Pdgfra tgcaaattgacatagaaggagaag gccctgtgaggagacagc 
PPAR gamma gaaagacaacggacaaatcacc gggggtgatatgtttgaacttg 
 
3.11. Gene array 
Purified total RNA from FACS-isolated cells was amplified using the Ovation PicoSL 
WTA System V2 kit (NuGEN Technologies). Per sample, 2 µg amplified cDNA was 
Cy3-labeled using the SureTag DNA labeling kit (Agilent). Hybridization to 8x60K 
60mer oligonucleotide spotted microarray slides (Agilent catalog gene expression 
microarray for Mouse, v2 8x60K, design ID 074809) and subsequent washing and 
drying of the slides was performed following the Agilent hybridization protocol in 
Agilent hybridization chambers, with the following modifications: 2 µg of the labeled 
cDNA were hybridized for 22h at 65°C. The cDNA was not fragmented before 
hybridization. The dried slides were scanned at 2 µm/pixel resolution using the 
InnoScan is900 (Innopsys). Image analysis was performed with Mapix 6.5.0 
software, and calculated values for all spots were saved as GenePix results files. 
Stored data were evaluated using the R software (“R: The R Project for Statistical 
Computing,” n.d.) and the limma package (Smyth, 2005) from BioConductor 
(Gentleman et al., 2004). Log2 mean spot signals were taken for further analysis. 
Data was background corrected using the NormExp procedure on the negative 
control spots and quantile-normalized (Smyth, 2005; Smyth and Speed, 2003) before 
averaging. Log2 signals of replicate spots were averaged, and from several different 
probes addressing the same gene only the probe with the highest average signal 
was used. Genes were ranked for differential expression using a moderated t-statistic 
(Smyth, 2005). Pathway analyses were done using gene set tests on the ranks of the 
t-values (Smyth, 2005, 2004). Pathways were taken from the KEGG database 
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(http://www.genome.jp/kegg/pathway.html).  Heatmaps were generated from the 
normalized log2 spot intensities (I) and show the gene-wise z-values (where 
    /j jz I mean I SD I   for 1j n ). The microarray data are available in GEO 
(GSE87683). 
 
3.12. Statistical analysis and figure assembly 
 
Quantitative data were assembled using GraphPad Prism software (GraphPad 
Software) and presented as average values +/- S.E.M. Statistical analyses were 
performed using Student’s t-test for comparing 2 groups or One-way ANOVA for 
comparing 3 or more groups. Results were considered significant if P<0.05. Figures 
were assembled using Adobe Photoshop CS5 or Adobe Illustrator Ai6. 
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4. Results 
 
4.1. PART I. Origin and fate of ACTA2+ cells during lung 
development 
4.1.1. FGF10+ cells contribute, to a limited extent, to ASMC formation 
The relatively stable -galactosidase expression in the Fgf10-LacZ enhancer-trap line 
allows following the distribution of FGF10+ cells and their immediate progenitors in 
the embryonic lung. Whole-mount LacZ staining revealed FGF10+ (LacZ+) cells in the 
distal mesenchyme as well as around the bronchi in E12.5 and E15.5 lungs (Fig. 4A-
E), as previously reported (Mailleux et al., 2005). These observations previously led 
to the conclusion that FGF10+ cells, which are originally found only in the distal 
mesenchyme (Bellusci et al., 1997a), migrate proximally and significantly differentiate 
along the ASMC lineage. Indeed, most of the ASMC regions were covered with 
LacZ+ cells. Using the Fgf10CreERT2; tdTomatoflox lineage-tracing tool, we also reported 
that FGF10+ cells, labeled at E11.5 via a single intraperitoneal injection of tamoxifen 
(Tam IP), give rise to ASMCs and VSMCs at E13.5 and E15.5, but to a lesser extent 
than observed with the Fgf10-LacZ line (El Agha et al., 2014) (Fig. 4F-J). In the 
absence of tamoxifen, tdTomato+ cells could not be observed in Fgf10CreERT2; 
tdTomatoflox lungs (Fig. S1A-B). Quantification of the IF showed that the proportion of 
SMCs arising from FGF10+ cells labeled at E11.5 was around 2±1%, indicating a 
minor contribution of FGF10+ cells to ASMC and VSMC lineages. A reason for this 
discrepancy in the relative contribution of FGF10+ cells to the ASMC lineage between 
the enhancer-trap line and the knock-in line could be the nature of the Fgf10-LacZ 
line. This transgenic line contains a minimal promoter for myosin light chain 1v 
(Mlc1v) upstream of the LacZ cassette but at the same time, it was found that the 
LacZ expression pattern mimicked Fgf10 expression in many organs. The Mlc1v-
LacZ transgene was found to be integrated 120 kb upstream of the Fgf10 gene and 
likely due to a positional effect, LacZ expression was found to mimic Fgf10 
expression (Kelly et al., 2001; Mailleux et al., 2005). In spite of all the in vivo and in 
vitro evidence to rule out the activation of the Mlc1v-LacZ cassette in the Fgf10-LacZ 
enhancer trap (see (Mailleux et al., 2005) for details), residual expression of Mlc1v-
LacZ can not be excluded with certainty.  
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Therefore, the LacZ expression pattern in the Fgf10-LacZ reporter line reflects the 
expression of Fgf10 (mostly distally) and likely to some extent the Mlc1v (mostly 
proximally). Altogether, our data show that FGF10+ cells are progenitors for ASMCs 
and VSMCs in the distal lung at early embryonic development. However, this 
contribution to the SMC lineage is minor (El Agha et al., 2014). 
 
Figure 4: Contribution of FGF10+ cells to the SMC lineage. (A-E) Fgf10 (LacZ) 
expression in Fgf10-LacZ lungs at E12.5 (A,B) and E15.5 (C,D). (E) Vibratome 
section of the lung shown in D. (F-J) Fgf10CreERT2; tdTomatoflox lungs induced with 
Tam IP at E11.5 and collected at E12.5 (F, G) and E15.5 (H,I). (J) 
Immunofluorescence for ACTA2 and tdTomato on the lung shown in (H). (J') High 
magnification of an airway showing tdTomato+ ACTA2+ cells. Tr – trachea, acc.lobe – 
accessory lobe, br. – bronchus, ht – heart, d.e. – distal epithelium, β-gal – β-
galactosidase, Tam IP – tamoxifen intraperitoneal injection, ACTA2 – alpha smooth 
muscle actin. N = 3 for all experiments. Scale bars: 200 μm in A; 170 μm in F; 60 μm 
in B, G; 450 μm in C, H; 220 μm in D, I; 50 μm in E; 130 μm in J. (Moiseenko et al., 
2017, Stem Cells, manuscript accepted for publication) 
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4.1.2. FGF10+ and GLI1+ domains are for the most part mutually exclusive at 
E12.5 
SHH signaling is critical for SMC formation as Shh KO lungs show complete absence 
of ACTA2+ cells (Miller et al., 2004; Pepicelli et al., 1998). SHH, expressed at high 
levels in the distal lung epithelium, acts on the mesenchyme and inhibits Fgf10 
expression (Bellusci et al., 1997a, 1996). In order to validate this finding, the 
expression pattern of LacZ in Fgf10-LacZ and Gli1LacZ lungs (Gli1 is a reporter for the 
activation of SHH signaling) at E12.5 was examined (Fig. 5). FGF10+ cells were 
observed mostly in the submesothelial mesenchyme whereas GLI1+ cells were 
mostly abundant in the subepithelial mesenchyme, and to a lower extent in the 
submesothelial mesenchyme. Both lines showed LacZ+ cells in the mesothelium. 
 
Figure 5: Fgf10-LacZ and Gli1LacZ are expressed in different mesenchymal 
areas. (A-D) Immunofluorescence for β-galactosidase on lungs at E12.5 of Fgf10-
LacZ (A,C) and Gli1LacZ (B,D). Dashed line divides sub-mesothelial mesenchyme and 
sub-epithelial mesenchyme. N = 3 for both experiments. Scale bar: 150 μm in A, B; 
35 μm in C; 40 μm in D. 
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4.1.3. GLI1+ cells give rise to most SMCs but do not exclusively differentiate 
along the SMC lineage 
In order to verify whether SMCs express GLI1 at E11.5, we analyzed Gli1LacZ lungs 
and we could not identify LacZ+ cells in the SMC layer at this time point (Fig. 6A,B).  
 
Figure 6: GLI1+ and AXIN2+ cells are not present in the SMC layer at E11.5. (A) 
Immunofluorescence for β-galactosidase on Gli1LacZ lungs at E11.5. High 
magnification of ASMCs is shown in (B-B’). (C) Immunofluorescence for β-
galactosidase on Axin2LacZ lungs at E11.5. High magnification of ASMCs is shown in 
(D-D”) Note the absence of β-galactosidase signal in ACTA2+ cells. N = 3. Scale bar: 
100 μm in A; 80 μm in C; 50 μm in B, D. (Moiseenko et al., 2017, Stem Cells, 
manuscript accepted for publication) 
 
We then set out to test the specificity of the GLI1+ lineage in terms of differentiation 
into SMCs, pregnant mice carrying Gli1CreERT2; tdTomatoflox embryos received a Tam-
IP injection at E11.5 and lungs were harvested at E12.5 and placed on nucleopore 
filters for live imaging for 3 days. The tdTomato signal expanded and labeled ring-like 
structures around the trachea and main bronchi. In addition, many tdTomato+ cells 
were observed throughout the lung mesenchyme (Fig. 7A-D). Similar imaging using 
Acta2-CreERT2; tdTomatoflox lungs showed that most tdTomato+ SMCs were located 
in proximal regions and expanded distally along the bronchi (Fig. 7E-H). Interestingly, 
few tdTomato+ cells were found in the distal mesenchyme. The differences in terms 
of localization and behavior of tdTomato+ cells between the Gli1 and Acta2 driver 
lines suggest that the GLI1+ lineage does not only contain SMC progenitors. 
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Figure 7: Distribution of GLI1+ and ACTA2+ cells labeled at E11.5 in the E12.5 
developing lung. (A-D) Single images from live imaging with Gli1CreERT2; tdTomatoflox 
tdTomatoflox lungs at E12.5 + 12, 24 and 50 hours. Note the intensity of tdTomato 
signal and appearance of ring like structures around trachea and main bronchi 
displaying contribution of GLI1+ cells to SMC lineage. Also note the presence of 
tdTomato+ cells in the mesenchyme throughout the lung. (E-H) Single images from 
live imaging with Acta2-CreERT2; tdTomatoflox lungs at E12.5 + 12, 24 and 50 hours. 
Note how tdTomato signal expands from proximal labeled SMCs distally along the 
bronchi. Note the presence of few tdTomato+ cells in distal mesenchyme. h – hours. 
N = 3 for both experiments. Scale bar: 500 μm in A-H. (Moiseenko et al., 2017, Stem 
Cells, manuscript accepted for publication) 
The Gli1CreERT2; tdTomatoflox line was also used to label GLI1+ cells at E11.5 and the 
lungs were harvested at E18.5. IF for ACTA2 was carried out and the contribution of 
GLI1+ cells to the SMC lineage was quantified (N=3). No tdTomato signal was 
observed in Gli1CreERT2;Tomatoflox lungs not treated with tamoxifen (Fig. S1E,F). The 
results showed that the majority of ACTA2+ cells were also tdTomato+ (72±3% for 
VSMCs and 97±2% for ASMCs) (Fig. 8A-C,E,F). Interestingly, most tdTomato+ cells 
in the quantified areas were ACTA2- parenchymal cells (71±2%) (Fig. 8D,G). Flow 
cytometry was also used and the initial gating for all experiments was set up to select 
live cells based on forward/side scatter profiles and exclude cell debris and highly 
granulated cells (Fig. S2). The analysis revealed that out of the total tdTomato+ cells 
in the lung (representing 13±2% of the total cell suspension at E18.5), only 9±1% 
were ACTA2+. In comparison, out of the total ACTA2+ cells (representing 4±1% of the 
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total cell suspension at E18.5), only 28±4% were tdTomato+ (Fig. 8H). The difference 
in the results between IF and flow cytometry might reflect the difference in sensitivity 
between the two approaches.  
 
Figure 8: Contribution of GLI1+ cells labeled at E11.5 to the SMC lineage. (A-D) 
Immunofluorescence for ACTA2 on Gli1CreERT2; tdTomatoflox lungs induced at E11.5 
and analyzed at E18.5. Merged and single-channel images of the boxes shown in (A) 
are shown for VSMCs (B-B’’), ASMCs (C-C’’’) and parenchymal cells (D-D’’). (E-G) 
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Quantification of tdTomato+ cell contribution to VSMCs (E) and ASMCs (F). Note that 
most of the tdTomato+ are in parenchymal areas (G). (H) Flow cytometry analysis of 
E18.5 Gli1CreERT2; tdTomatoflox lungs labeled at E11.5. Fl.Cyt. – Flow cytometry, FSC 
– forward scatter. N = 3. Scale bar: 200 μm in A; 36 μm in B-D. (Moiseenko et al., 
2017, Stem Cells, manuscript accepted for publication) 
In a previous study it was shown that GLI1+ cells labeled at E10.5 and E11.5 give 
rise exclusively to SMCs and alveolar MYF, and do not give rise to other 
mesenchymal lineages such as lipofibroblasts (Li et al., 2015). In our work, staining 
for PLIN2 (ADRP), a lipofibroblast marker, showed that a proportion of tdTomato+ 
cells were indeed ADRP+. Flow cytometry analysis using the neutral lipid stain, 
LipidTOX, revealed that out of the total tdTomato+ cells in the lung (representing 
13±2% of the total cell suspension at E18.5), 46±3% were LipidTOX+ (Fig. 9). On the 
other hand, out of the total LipidTOX + cells (representing 26±3% of the total cell 
suspension at E18.5), 18±1% were tdTomato+. Altogether, the data revealed that the 
GLI1+ lineage not only contributes to the ASMC and VSMC lineages, but also to 
lipofibroblasts, in addition to other undetermined lineages. 
 
Figure 9: GLI1+ cells partially give rise to lipofibroblasts. (A-B) 
Immunofluorescence for PLIN2 on Gli1CreERT2; tdTomatoflox lungs induced at E11.5 
and analyzed at E18.5. (B) High magnification image of parenchymal cells. (C) Flow 
cytometry analysis of E18.5 Gli1CreERT2; tdTomatoflox lungs labeled at E11.5. PLIN2 – 
perilipin 2 (adipose differentiation-related protein). N = 3. Scale bar: 70 μm in A; 35 
μm in B. (Moiseenko et al., 2017, Stem Cells, manuscript accepted for publication) 
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4.1.4. GLI1+ cells significantly contribute to the alveolar MYF lineage during the 
alveolar stage of lung development 
In another set of experiments, GLI1+ cells were labeled during the end of the saccular 
stage (between PN2 and PN5 via tamoxifen-containing food) and lungs were 
analyzed (N=3) during the process of alveolarization at PN15. Elastin-secreting 
ACTA2+ alveolar MYFs are critical players during this developmental stage. The 
results showed that most tdTomato+ cells were located in secondary septa and were 
ACTA2+ (Fig. 10A,C,F). Quantification of IF showed that under these experimental 
conditions, around 50±3% of alveolar MYFs in secondary septa were tdTomato+ (Fig. 
10E). By contrast, continuous labeling between PN2 and PN14 revealed almost all 
the alveolar MYFs in secondary septa were tdTomato+ (Fig. 10B,D,E). Moreover, 
ASMCs were also significantly labeled in both experimental conditions (Fig. 10G), 
with only minor labeling of VSMCs (Fig. 10H). 
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Figure 10: Contribution of GLI1+ cells labeled at PN2-PN5 or PN2-PN14 to the 
ACTA2+ lineage. (A-D) Immunofluorescence for ACTA2 on Gli1CreERT2; tdTomatoflox 
lungs at PN14. (C,D) High-magnification images of the boxes shown in (A) and (B) 
showing ACTA2+ tdTomato+ alveolar MYFs marked by arrows and an ACTA2+ 
tdTomato- cell marked by an asterisk. Note that when induced at PN2-PN14 (B,D) 
tdTomato+ cells significantly give rise to ACTA2+ cells as compared to labeling at 
PN2-PN5 (A,C). (E) Quantification of immunofluorescence showing that the majority 
of alveolar MYFs are tdTomato+ when cells are labeled between PN2 and PN14. 
Less alveolar MYFs are tdTomato+ when cells are labeled between PN2 and PN5. 
(F) Under both labeling conditions, the majority of tdTomato+ cells are ACTA2+ in 
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secondary septa. (G, H) A significant proportion of ASMCs and a minor proportion of 
VSMCs are labeled in both approaches. N = 3 for both experiments. PN – postnatal. 
Scale bar: 70 μm in A, B; 18 μm in C, D. **** P<0.0001. (Moiseenko et al., 2017, 
Stem Cells, manuscript accepted for publication) 
 
4.1.5. WT1+ cells contribute to the SMC lineage in a minor fashion 
The Wt1CreERT2; tdTomatoflox line was used to label WT1+ cells at E11.5 and lungs 
were analyzed by IF at E18.5 (N=3). As expected, the mesothelium was abundantly 
labeled as well as individual cells in the parenchyma (Fig. 11A-D). However, 
quantification of tdTomato+ ACTA2+ cells in the vascular compartment indicated no 
contribution of these cells to VSMCs proximally, and only 1±1% of these cells 
contributed to VSMCs distally (Fig. 11E).  A similar observation was made for 
ASMCs (1±1% proximally and 7±5% distally) (Fig. 11F). Finally, 72±3% of tdTomato+ 
cells were ACTA2-, and located in the parenchyma (Fig. 11G). 
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Figure 11: Contribution of WT1+ cells labeled at E11.5 to the SMC lineage. (A-D) 
Immunofluorescence for ACTA2 on Wt1CreERT2; tdTomatoflox lungs at induced at 
E11.5 and analyzed at E18.5. Merged and single-channel images of the boxes 
shown in (A) are shown for VSMCs (B-B’’), ASMCs (C-C’’’) and parenchymal cells 
(D-D’’). (E-G) Quantification of tdTomato+ cell contribution to proximal and distal 
VSMCs (E) and ASMCs (F). Note that most of the tdTomato+ are in parenchymal 
areas (G). N = 3. Scale bar: 200 μm in A; 20 μm in B-D.  (Moiseenko et al., 2017, 
Stem Cells, manuscript accepted for publication) 
 
4.1.6. AXIN2+ cells give rise to most SMCs but do not exclusively differentiate 
along the SMC lineage 
Considering the proposed role of WNT signaling in SMC formation (Cohen et al., 
2009; Li et al., 2015), we decided to analyze the contribution of AXIN2+ cells to this 
lineage. In order to verify whether ASMCs express AXIN2 at E11.5, the Axin2LacZ 
reporter line was used and ACTA2/β-galactosidase double staining showed that 
ASMCs do not express AXIN2 at this time point (Fig. 6C,D). The Axin2CreERT2 line was 
then used to determine the fate of cells undergoing active WNT signaling during 
development. No tdTomato signal was observed in Axin2CreERT2; tdTomatoflox  lungs 
not treated with tamoxifen (Fig. S1I,J). AXIN2+ cells were labeled at E11.5 and lungs 
were analyzed at E18.5 (N=3). TdTomato+ cells showed a high level of contribution to 
the VSMC and ASMC lineages, similarly to GLI1+ cells (Fig. 8). IF showed that most 
of ACTA2+ SMCs were also tdTomato+ (77±8% for VSMCs and 97±3% for ASMCs) 
(Fig. 12A-C,E,F). Similar to the results obtained with the GLI1+ lineage, most of 
tdTomato+ cells in the quantified areas were ACTA2- parenchymal cells (70±1%) 
(Fig. 12D,G). 
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Figure 12: Contribution of AXIN2+ cells labeled at E11.5 to the SMC lineage. (A-
D) Immunofluorescence for ACTA2 on Axin2CreERT2; tdTomatoflox lungs at E18.5. 
Merged and single-channel images of the boxes shown in (A) are shown for VSMCs 
(B-B’’), ASMCs (C-C’’’) and parenchymal cells (D-D’’). (E-G) Quantification of 
tdTomato+ cell contribution to VSMCs (E) and ASMCs (F). Note that most of the 
tdTomato+ are in parenchymal areas (G). High magnification images of (B) VSMCs, 
(C) ASMCs, (D) parenchymal cells. N = 3. Scale bar: 200 μm in A; 40 μm in B-D. 
(Moiseenko et al., 2017, Stem Cells, manuscript accepted for publication) 
 
4.1.7. Proximal ACTA2+ cells labeled at E11.5 do not give rise to SMCs distally 
The Acta2-CreERT2 line was used to investigate whether differentiated SMCs can 
serve as progenitors for newly forming SMCs. No tdTomato signal was observed in 
Acta2-CreERT2; tdTomatoflox lungs not treated with tamoxifen (Fig. S1M,N). SMCs 
were labeled at E11.5 and lungs were analyzed at E18.5 (N=3). The results showed 
that most of the labeled cells were present proximally rather than distally for both 
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ASMCs (94±3% vs. 24±4%; proximal vs. distal, respectively) and VSMCs (95±2% vs. 
32±5%; proximal vs. distal, respectively) (Fig. 13A,B,D,F,G). This suggests that 
differentiated SMCs have very limited progenitor-like characteristics and therefore do 
not massively give rise to distal SMCs. Interestingly, tdTomato+ cells were also 
observed in the parenchyma throughout the lung (2-4 cells per section at 63X 
magnification) (Fig. 13C, E, H). 
When ACTA2+ cells were labeled at E15.5 and lungs were analyzed at E18.5 (N=3), 
an increase in the number of tdTomato+ ACTA2+ cells was observed throughout the 
lung (Fig. 13I-P). By contrast to labeling at E11.5, ASMCs and VSMCs were labeled 
in both proximal and distal regions of the lung - ASMCs (97±1% vs. 87±5%; proximal 
vs. distal, respectively) and VSMCs (96±1% vs. 85±4%; proximal vs. distal, 
respectively) (Fig. 13J,L,N,O).  In addition, an increase in the number of parenchymal 
tdTomato+ cells was observed (8-10 cells per section when induced at E15.5 vs. 2-4 
cells per section when induced at E11.5) (Fig. 13P). 
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Figure 13: Contribution of ACTA2+ cells labeled at E11.5 and E15.5 to the SMC 
lineage. (A-E). Immunofluorescence for ACTA2 on Acta2-CreERT2; tdTomatoflox 
lungs labeled at E11.5 and sacrificed at E18.5. (B-E) High-magnification images of 
proximal and distal ACTA2+ tdTomato+ ASMCs and VSMCs as well as ACTA2- 
tdTomato+ parenchymal cells. Note that labeled tdTomato+ cells are located more 
proximally, but not distally. (F) Quantification of ASMC coverage by tdTomato signal. 
(G) Quantification of VSMCs coverage by tdTomato signal. (H) Quantification of 
parenchymal tdTomato+ cells. (I-M) Immunofluorescence for ACTA2 on Acta2-
CreERT2; tdTomatoflox lungs labeled at E15.5 and sacrificed at E18.5. (J-M) High-
magnification images of proximal and distal ACTA2+ tdTomato+ ASMCs and VSMCs 
as well as ACTA2- tdTomato+ parenchymal cells. Note the significant colocalization of 
an ACTA2 stain and tdTomato signal both proximally and distally. (N) Quantification 
of ASMC coverage by tdTomato signal. (O) Quantification of VSMC coverage by 
tdTomato signal. (P) Quantification of parenchymal tdTomato+ cells. Aw – airway, V - 
blood vessel, prox. – proximal, dist. – distal. N=3 for both experiments. Scale bar: 
400 μm in A, I; 20 μm in B-E, J-M. *** P<0.001. (Moiseenko et al., 2017, Stem Cells, 
manuscript accepted for publication) 
 
4.1.8. Parenchymal ACTA2low lineage contains progenitors for alveolar 
myofibroblasts that appear postnatally 
Next, we tested whether parenchymal ACTA2low tdTomato+ cells at E18.5, which 
trace back to E11.5 and more significantly to E15.5, are progenitors for alveolar 
MYFs. To test this hypothesis, the Acta2-CreERT2; tdTomatoflox line was used to 
label ACTA2+ cells at E15.5 and lungs were harvested at PN14 (N=6). Alveolar MYFs 
are known to produce elastin (ELN), deposition of which is critical for maintaining the 
alveolar integrity and allowing alveoli to stretch during inhalation (Dickie et al., 2008). 
Our results showed the presence of tdTomato+ ACTA2+ ELN+ cells at PN14 (Fig. 
14B,E). Out of the total tdTomato+ cells that are not located around airways and 
within vessels, 90±2% were alveolar MYFs at PN14, based on two criteria: 
expression of ACTA2/ELN and location at the tip of secondary septa (Fig. 14D). 
9±2% of tdTomato+ cells were ACTA2- at PN14 (Fig. 14D). In addition, out of the total 
alveolar MYFs, 36±3% were tdTomato+ (Fig. 14C). Additionally, flow cytometry 
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revealed that 24±3% of tdTomato+ cells labeled at E15.5 were PDGFRα+ at PN14 
(Fig. 14F).  
 
Figure 14: Parenchymal ACTA2low cells labeled at E15.5 give rise to PDGFRα+ 
alveolar MYFs at PN14. (A) Immunofluorescence for ACTA2 on Acta2-CreERT2; 
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tdTomatoflox lungs at PN14. (B-B’’’) Merged and single-channel high magnification 
images of the box shown in (A) showing ACTA2+ tdTomato+ alveolar MYFs marked 
by arrows, ACTA2+ tdTomato- cells are marked with asterisks. (C,D) Quantification of 
ACTA2+ and tdTomato+ cells in the tips of secondary septa. (E) Merged and single-
channel images of immunofluorescence for elastin (ELN) on Acta2-CreERT2; 
tdTomatoflox lungs at PN14. tdTomato+ ELN+ cells are marked by arrows. (F) Flow 
cytometry analysis of Acta2-CreERT2; tdTomatoflox lungs (Tam IP E15.5) at PN14 
based on tdTomato expression and PDGFRα staining. ELN – elastin, PDGFRα – 
platelet-derived growth factor receptor alpha. N = 6. Scale bar: 150 μm in A; 35 μm in 
B; 40 μm in E. **** P<0.0001. (Moiseenko et al., 2017, Stem Cells, manuscript 
accepted for publication) 
Since PDGFRα is believed to be a marker for alveolar MYFs and/or their progenitors, 
FACS was used to sort various tdTomato+ cell populations based on ACTA2 and 
PDGFRα expression at E18.5. TdTomato+ cells labeled at 15.5 and collected at 
E18.5 represented 2±0.3% of total lung cells (Fig. 15A). Further analysis based on 
PDGFRα and ACTA2 expression revealed the presence of three distinct cell 
populations (N=9). In particular, the AMCS and VSMCs (tdTomato+ ACTA2high 
PDGFRα-) represented around 15±1% of total tdTomato+ cells, while alveolar MYF 
progenitors (tdTomato+ ACTA2low PDGFRα+) represented around 21±4% of total 
tdTomato+ cells. QPCR-based validation of these two pools of lineage-traced cells 
confirmed that alveolar MYF progenitors expressed high levels of Pdgfra and Eln, 
while ASMCs and VSMCs expressed high levels of Acta2. Note that Eln was 
upregulated by 400 fold in alveolar MYF progenitors compared to ASMCs and 
VSMCs (Fig. 15B). 
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Figure 15: Analysis of different ACTA2+ cell populations labeled at E15.5 and 
collected at E18.5. (A) Gating strategy for isolating various tdTomato+ cell 
populations (induced at E15.5 and collected at E18.5) based on ACTA2 and 
PDGFRα expression. (B) Gene expression analysis of sorted cells. ELN – elastin, 
PDGFRα – platelet-derived growth factor receptor alpha. N=9. * P<0.05, ** P<0.01. 
(Moiseenko et al., 2017, Stem Cells, manuscript accepted for publication) 
Next, gene arrays were carried out on isolated lineage-labeled cells (3 independent 
experiments, 3 lungs used per pool): ASMCs and VSMCs (ACTA2high PDGFRα-), 
alveolar MYF progenitors (ACTA2low PDGFRα+) and ACTA2low PDGFRα- cells (called 
intermediate undifferentiated progenitors or INMs). Note that the minor ACTA2high 
PDGFRα+ pool, which represented around 2±1% of the overall tdTomato+ population, 
was not considered for further analysis. Most changes in gene expression levels 
occurred between SMCs and alveolar MYF progenitors. The INM pool was very 
similar to the SMC pool in regards to gene expression levels (Fig. 16A). The top 100 
up/downregulated genes according to fold-change values are represented in the heat 
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maps (Fig. 16A). KEGG analysis revealed that in contrast to SMCs, alveolar MYF 
progenitors display an upregulation of the genes related to sonic hedgehog, WNT 
and FGF signaling pathways – the known regulators of smooth muscle cell 
differentiation (Fig 16B,C; Table 4). Transcriptomic signatures of different ACTA2-
derived populations were identified and the results showed genes enriched either in 
ASMCs and VSMCs or in alveolar MYF progenitors at E18.5 (Supplementary Table 1 
and 2). Among the highly upregulated genes in alveolar MYF progenitors are 
members of the WNT signaling pathway, such as WNT inhibitory factor 1 (Wif1), 
Lymphoid enhancer binding factor 1 (Lef1), Transcription factor 7 (T cell specific) 
(Tcf7), and WNT family member 5a (Wnt5a). Members of the Transforming growth 
factor β (TGFβ) pathway were also enriched in alveolar MYF progenitors, such as 
Transforming growth factor β receptor 3 (Tgfbr3) and Bone morphogenetic protein 4 
(Bmp4), confirming the importance of this pathway in alveolar MYF differentiation. 
Genes enriched in SMCs were mostly structural proteins – actinin, myosin, troponin, 
and proteins regulating muscle contraction. Signaling pathways such SHH, WNT, 
FGF and TGFβ were downregulated, suggesting that these pathways mostly regulate 
the fate of progenitor cells and are significantly inactive in fully differentiated SMCs, 
the main function of which is contraction. 
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Figure 16: Genes and pathways regulated in ACTA2-derived cell populations. 
(A) Top 50 genes specifically upregulated and top 50 genes downregulated in 
alveolar MYF progenitors (aMYF prog.) in comparison to airway and vascular SMCs 
(SMC) and intermediate undifferentiated progenitors (INM). (B, C) KEGG analysis of 
specific signaling pathways – (B) Hedgehog and (C) WNT, showing that the majority 
of the genes in these pathways are upregulated in alveolar MYF progenitors versus 
SMCs. (Moiseenko et al., 2017, Stem Cells, manuscript accepted for publication) 
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Table 4. Genes related to SHH, WNT and FGF signaling pathways upregulated 
in alveolar MYF progenitors in contrast to SMCs. 
 
Genes upregulated in alveolar MYF progenitors vs. SMCs 
Sonic hedgehog signaling WNT signaling 
Gli1 (GLI-Kruppel family member GLI1) 
FC=7.26, p<0.0001 
Wif1 (Wnt inhibitory factor 1) FC=235.57, 
p<0.0001 
Bmp4 (bone morphogenetic protein 4) 
FC=5.34, p<0.001 
Lef1 (lymphoid enhancer binding factor 1) 
FC=32, p<0.0001 
Hhip (Hedgehog-interacting protein) 
FC=5.03, p<0.005 
Tcf7 (transcription factor 7, T cell specific) 
FC=16.56, p<0.0001 
Bmp2 ( bone morphogenetic protein 2) 
FC=5.1, p<0.01 
Wnt5a (wingless-type MMTV integration 
site family, member 5A) FC=11.47, 
p<0.0001 
Sufu ( suppressor of fused homolog 
(Drosophila)) FC=4.69, p<0.05 
Fzd1 (frizzled homolog 1 (Drosophila) 
FC=9.45, p<0.0001 
Gli3 (GLI-Kruppel family member GLI3) 
FC=3.86, p<0.01 
Invs  (Inversin) FC=9.25, p<0.0001 
Ptch1 (patched homolog 1) FC=3.81, 
p<0.001 
Daam2 (dishevelled associated activator 
of morphogenesis 2) FC=7.94, p=0.09 
Gas1 (growth arrest specific 1) FC=3.14, 
p<0.01 
Wnt5b (wingless-type MMTV integration 
site family, member 5B) FC=6.68, 
p<0.001 
Smo (smoothened homolog (Drosophila) 
FC=2.81, p<0.01 
Wnt9a (wingless-type MMTV integration 
site family, member 9A) FC=5.81, p<0.01 
Csnk1d (casein kinase 1, delta) 
FC=2.23, p<0.01 
Nfatc4 (nuclear factor of activated T cells, 
cytoplasmic, calcineurin dependent 4) 
FC=5.73, p<0.001 
 Tle1 (transducin-like enhancer of split 1, 
homolog of Drosophila E(spl) ) FC=5.62, 
p<0.001 
Fibroblast growth factor signaling Lrp1 (low density lipoprotein receptor-
related protein 1)) FC=4.89, p<0.0001 
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Fgf10 (fibroblast growth factor 10) 
FC=29.04, p<0.0001 
Axin2 FC=4.79, p<0.001 
Fgf7 (fibroblast growth factor 7) 
FC=20.82, p<0.01 
Fzd10 (frizzled homolog 10 (Drosophila) 
FC=4.59, p<0.05 
Map3k6 (mitogen-activated protein 
kinase 6) FC=9.19, p<0.01 
Prickle2 (prickle homolog 2 (Drosophila) 
FC=4.5, p<0.05 
Fgf11 (fibroblast growth factor 11) 
FC=8.22, p=0.08 
Dkk3 (dickkopf homolog 3 (Xenopus 
laevis) FC=4.2, p<0.01 
Fgf2 (fibroblast growth factor 2) 
FC=7.36, p<0.05 
Wnt11 (wingless-type MMTV integration 
site family, member 11) FC=4.17, p<0.01 
Fgf18 (fibroblast growth factor 18) 
FC=7.41, p<0.01 
Prkca (protein kinase C, alpha) FC=4.03, 
p<0.001 
Fgf5 (fibroblast growth factor 5) 
FC=4.86, p=0.13 
Tbl1xr1 (transducin (beta)-like 1X-linked 
receptor 1) FC=3.14, p<0.01 
Ptpn5 (protein tyrosine phosphatase, 
non-receptor type 5) FC=4.14, p<0.05 
Bambi (BMP and activin membrane-
bound inhibitor) FC=3.12, p=0.05 
Prkca (protein kinase C, alpha) FC=4.03, 
p<0.001 
Ep300 (E1A binding protein p300) 
FC=2.73, p<0.05 
Fgfr4 (fibroblast growth factor receptor 4) 
FC=3.84, p<0.05 
Nlk  (nemo like kinase) FC=2.67, p<0.01 
Ngf (nerve growth factor) FC=2.91, 
p<0.05 
Plcb1 (phospholipase C, beta 1) FC=2.64, 
p<0.05 
Fgf17 (fibroblast growth factor 17) 
FC=2.83, p<0.05 
Nkd1 (naked cuticle 1 homolog 
(Drosophila) FC=2.57, p<0.005 
Fgfbp3 (fibroblast growth factor binding 
protein 3)) FC=2.62, p<0.05 
Mmp7 (matrix metallopeptidase 7) 
FC=2.55, p=0.12 
Fgfr1 (fibroblast growth factor receptor 1) 
FC=2.46, p<0.01 
Fosl1 (fos-like antigen 1) FC=2.53, p=0.36 
Fgf12 (fibroblast growth factor 12) 
FC=2.03, p=0.44 
Smad3 (SMAD family member 3) 
FC=2.34, p<0.05 
 Myc (myelocytomatosis oncogene) 
FC=2.03, p=0.06 
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4.1.9. Differentiated SMCs as well as progenitors for alveolar MYFs and mature 
alveolar MYFs do not proliferate 
To assess the proliferation status of different ACTA2+ populations lungs were stained 
for Ki67, a cellular marker for proliferation. No proliferation were observed in ASMCs 
when labeled at E15.5 and analyzed at E18.5 and PN14 (Fig 17A,C). No proliferation 
was also observed for alveolar MYF progenitors as well as mature alveolar MYFs 
(Fig 17B,D).  
 
Figure 17: Parenchymal ACTA2+ cells labeled at E15.5 do not proliferate at 
E18.5 or at PN14. (A-D) Merged and single channel images of immunofluorescence 
for tdTomato and KI67 on Acta2-CreERT2; tdTomatoflox lungs labeled at E15.5 and 
sacrificed at (A, B) E18.5 and (C, D) PN14 showing no proliferation in both (A, C) 
ASMCs and (B, D) parenchymal cells for both time points. N = 3 for both 
experiments. Scale bar: 40 μm in all panels. (Moiseenko et al., 2017, Stem Cells, 
manuscript accepted for publication) 
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4.1.10. Alveolar MYFs do not disappear from the lung after alveolarization  
Alveolar MYFs play an important role in creating alveoli. But after the process of 
alveolarization is finished alveolar MYFs were believed to disappear from the lung 
(Kapanci et al., 1995; Yamada et al., 2005). However, when labeling at PN2-5, 
ACTA2+ MYFs that are present with high number in parenchyma and show high 
ACTA2 expression at PN14 (Fig. 18A) are still present in lung parenchyma at PN30 
and PN60 (Fig. 18B,C) but with lower number and with lower ACTA2 expression (Fig. 
18D,E). 
 
 
Figure 18: ACTA2+ alveolar MYFs labeled at PN2-PN5 are present in lung at 
PN30 and PN60 but with less number and lower ACTA2 expression than at 
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PN14. (A-C) Immunofluorescence for ACTA2 (green) in lungs of Acta2-CreERT2; 
tdTomatoflox labeled at PN2-PN5 and sacrificed at (A) PN14, (B) PN30 and (C) PN60 
showing the presence of tdTomato+ cells in parenchyma, but with lower number and 
lower ACTA2 expression. A’- higher magnification shown in A, A’’- higher 
magnification shown in A’. (D) Quantification of tdTomato+ cells in parenchyma. (E) 
Quantification of ACTA2 signal intensity in tdTomato+ cells. PN2 – postnatal day 2, 
Tam – tamoxifen, aver. – average, pix. – pixel, int. - intensity, tdTom - tdTomato. N = 
3 for all experiments. Scale bar: 100 μm in A, 25 μm in B, 7 μm in C. * P<0.05, *** 
P<0.001, **** P<0.0001. 
 
4.2. PART II. Origin and fate of activated MYFs in bleomycin-
induced lung fibrosis 
 
4.2.1. Pre-existing SMCs do not give rise to activated MYFs in bleomycin 
induced lung fibrosis 
In some diseases pre-existing SMCs were shown to give rise to pathological 
remodeled structures. It was shown that in hypoxia-induced pulmonary hypertension 
SMCs in the remodeled vessels originate from pre-existing SMCs (Sheikh et al., 
2014). In our work we were interested to investigate whether pre-existing ASMCs 
and VSMCs give rise to activated MYFs in lung fibrosis. Using Acta2-CreERT2; 
tdTomatoflox mice pre-existing SMCs were labeled before they were treated either 
with saline or bleomycin to induce lung fibrosis (Fig. 20A,C). Before the intratracheal 
installation of bleomycin, mice were fed tamoxifen-containing food for two weeks 
following two weeks of feeding with normal food to ensure enough time for tamoxifen 
clearance (Fig. 20C). The peak of fibrosis is happening at day 14 after bleomycin 
treatment, at this time point the number of fibroblasts and severity of fibrosis are 
usually the highest.  At day 14 after bleomycin treatment lung fibrosis was confirmed 
using forced oscillation plethysmography, which revealed decreased lung compliance 
in bleomycin-treated mice in comparison to saline-treated mice, hematoxylin and 
eosin (H&E) staining also confirmed the presence of fibrotic tissue in the lung (Fig. 
19). 
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Figure 19: Fibrosis validation in Acta2-CreERT2; tdTomatoflox mice at day 14 
after saline or bleomycin treatment. (A) H&E staining of saline treated lungs at day 
14 after the treatment. A higher magnification is show in (B). (C) H&E staining of 
bleomycin treated lungs (3.5 U/kg) at day 14 after the treatment. A higher 
magnification is show in (D). (E) Lung function measurement demonstrating 
decreased compliance in bleomycin treated group in comparison to control group. 
BLM – bleomycin, SAL – saline, Crs - compliance. N = 4 for SAL, N = 7 for BLM. 
Scale bar: 2 mm in A and C, 200 μm in B and D. ** P<0.01. (El Agha et al., 2017) 
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Lungs from day 14 after bleomycin treatment were immunostained for ACTA2 (a 
marker for SMCs and activated MYFs).  Efficiency of the labeling of ACTA2+ cells 
using Acta2-CreERT2; tdTomatoflox was 83.5% in saline treated lungs (Fig. 20I). The 
pre-existing ASMCs and VSMCs were found to express the lineage label tdTomato in 
both saline (Fig. 20B) and bleomycin-treated groups (Fig. 20D). A different result was 
observed for activated MYFs. ACTA2+ activated MYFs located in dense fibrotic areas 
did not express the lineage label tdTomato in bleomycin-treated lungs (Fig. 20E). 
This result suggests that pre-existing SMCs do not give rise to activated MYFs in 
lung fibrosis. FACS-based quantification supported the histological observation 
showing the increase in the number of ACTA2+ cells in bleomycin-treated lungs 
(1.8% out of total lung suspension), compared to saline-treated lungs (0.6%) (Fig. 
20F). There was no significant change in number of lineage-labeled tdTomato+ cells 
between two groups, showing that pre-existing SMCs do not significantly amplify 
after bleomycin treatment (Fig. 20G), and lineage-labeled tdTomato+ cells were 
mostly ACTA2+ (81.6-92.2%) (Fig. 20H). However, while 83% of ACTA2+ cells 
(SMCs) were lineage-labeled (tdTomato+) in the saline-treated group, only 52.7% of 
ACTA2+ cells (SMCs and activated MYFs) were lineage-labeled in the bleomycin-
treated group (Fig. 20I), showing that activated MYFs do not originate from pre-
existing ACTA2+ cells (SMCs). 
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Figure 20: Labeled pre-existing SMCs do not give rise to activated MYFs in 
lung fibrosis in Acta2-CreERT2; tdTomatoflox mice. (A) Schematic timeline of 
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tamoxifen and saline treatment. Mice received tamoxifen-containing food before 
saline was administered intra-tracheally. Lungs were harvested at day 14 after saline 
treatment (B) Immunofluorescence for ACTA2 in lungs treated with saline. DAPI, 
tdTomato and ACTA2 single channels are shown in addition to merged image. (C) 
Schematic timeline of tamoxifen and bleomycin treatment. Mice received tamoxifen-
containing food before bleomycin was administered intra-tracheally. Lungs were 
harvested at day 14 after saline treatment. (D-E) Immunofluorescence for ACTA2 in 
lungs treated with bleomycin. DAPI, tdTomato and ACTA2 single channels are 
shown in addition to merged image. High magnification images of the boxes in (D) 
are shown in (E). (F-I) FACS-based quantification of ACTA2+ and tdTomato+ 
populations in saline and bleomycin treated lungs at day 14 after treatment. BLM – 
bleomycin, SAL – saline, a – airway, v – vessel, ns – not significant. N = 4 for SAL, N 
= 6 for BLM. Scale bar: 250 μm in B and D, 50 μm in E. *P<0.05, ** P<0.01. (El Agha 
et al., 2017) 
 
4.2.2. Activated MYFs persist in the lung after fibrosis resolution and lose 
ACTA2 expression 
Since activated MYFs express ACTA2 it is possible to label and lineage-trace them 
using Acta2-CreERT2; tdTomatoflox mouse line. To validate this, Acta2-CreERT2; 
tdTomatoflox mice were treated with bleomycin and then fed tamoxifen-containing 
food between day 5 and 14 after bleomycin treatment (Fig. 21A).  At day 14 lungs 
were harvested and stained for ACTA2. Activated MYFs were labeled as 
demonstrated by co-localization of the ACTA2 and the tdTomato lineage label in 
fibrotic areas of bleomycin-treated lungs (Fig. 21B). Quantification of the 
immunofluorescence showed that 79.2% of lineage-labeled tdTomato+ cells were 
ACTA2+ at day 14 after bleomycin treatment (Fig. 21C). Such quantification was 
challenging since ACTA2 is not uniformly expressed in fibrotic regions and it was not 
easy to detect cell boundaries and co-localize nuclear and cytoplasmic tdTomato 
signal with cytoskeletal ACTA2. To strengthen these data, FACS-based 
quantification was made and results showed that labeling efficiency of SMCs and 
activated MYFs was 93.2% at day 14 after bleomycin treatment (Fig. 21M). FACS-
based quantification also revealed that 92.2% of lineage-labeled tdTomato+ cells 
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were ACTA2+ at day 14 after bleomycin treatment (Fig. 21L) (compared to 79.2% 
based on quantification of immunofluorescence). 
 
Figure 21: Labeled activated MYFs lose their myogenic phenotype during 
resolution of fibrosis. (A) Schematic timeline of bleomycin and tamoxifen 
treatment. Mice were treated with bleomycin and then received tamoxifen-containing 
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food between day 5 and 14 after bleomycin treatment. Lungs were harvested at day 
14 after bleomycin treatment. (B) Immunofluorescence for ACTA2 in lungs at day 14 
after bleomycin treatment. DAPI, tdTomato and ACTA2 single channels are shown in 
addition to merged image. (C) Quantification of the immunofluorescence shown in B 
and E. (D) Schematic timeline of bleomycin and tamoxifen treatment. Mice were 
treated with bleomycin and then received tamoxifen-containing food between day 5 
and 20 after bleomycin treatment. Lungs were harvested at day 60 after bleomycin 
treatment. (E) Immunofluorescence for ACTA2 in lungs at day 60 after bleomycin 
treatment. DAPI, tdTomato and ACTA2 single channels are shown in addition to 
merged image. (F-I) Gating strategy for FACS-based quantification of ACTA2+ and 
tdTomato+ cell populations. (J-M) FACS-based quantification of ACTA2+ and 
tdTomato+ cell populations in lung suspensions at day 14 and 60 after bleomycin 
treatment. BLM – bleomycin, FSC – forward scatter. N = 6-8 for BLM d14, N = 3 for 
BLM d60. Scale bar: 10 μm in B, 75 μm in E. *P<0.05, *** P<0.001. (El Agha et al., 
2017) 
To investigate the fate of activated MYFs after fibrosis resolution the time point of 60 
day after bleomycin treatment was chosen to ensure that lung fibrosis was 
adequately resolved (Fig. 21D). Resolution of fibrosis was confirmed by lung function 
measurements and H&E staining (Fig. 22). Interestingly, activated MYF descendants 
(lineage labeled activated MYFs) were observed in the lung after fibrosis resolution. 
Immunofluorescent staining and quantification of the immunofluorescent signal 
showed that only 11% of these cells were ACTA2+ (Fig. 21E,C). FACS-based 
quantification (Fig. 21F-I) supported histological findings, showing a decrease in the 
number of ACTA2+ cells at day 60 compared to day 14 (2% vs. 1.2%) after bleomycin 
treatment (Fig. 21J). The total number of tdTomato+ cells was unchanged between 
the two time points (2.3%-2.8%) (Fig. 21K), showing that these cells are not cleared 
from the lung after fibrosis resolution. Interestingly, only 49.6% of these lineage-
labeled tdTomato+ cells were ACTA2+ at day 60, in contrast to 92.2% at day 14 after 
bleomycin treatment (Fig. 21L), indicating that MYF descendants lose Acta2 
expression significantly. The majority of ACTA2+ cells at both day 14 (SMCs and 
activated MYFs) and day 60 (SMCs and activated MYF descendants) were 
tdTomato+ (93.2% and 92.5% respectively) (Fig. 21M), demonstrating that our 
lineage-tracing approach allowed to capture effectively the majority of ACTA2+ cells. 
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Figure 22: Fibrosis resolution validation in Acta2-CreERT2; tdTomatoflox mice at 
day 60 after saline or bleomycin treatment. (A) H&E staining of saline treated 
lungs at day 60 after the treatment. A higher magnification is show in (B). (C) H&E 
staining of bleomycin treated lungs at day 60 after the treatment. A higher 
magnification is show in (D). (E) Lung function measurement demonstrating no 
difference in compliance in bleomycin treated group in comparison to control group. 
BLM – bleomycin, SAL – saline, Crs - compliance. N = 3 for both groups. Scale bar: 2 
mm in A and C, 200 μm in B and D. ** P<0.01. (El Agha et al., 2017)  
4.2.3. Activated MYFs undergo a phenotypic switch after fibrosis resolution 
To investigate whether activated MYF transition to lipofibroblast-like phenotype after 
fibrosis resolution, immunofluorescence for the lipofibroblast marker (ADRP) and 
AECII marker (SFTPC) was performed. Lineage labeled tdTomato+ cells were 
ADRP+ and were found adjacent to SFTPC+ cells at day 60 after bleomycin treatment 
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(Fig. 23A). According to quantification of immunofluorescence out of total tdTomato+ 
cells 30.5% were ADRP+ at day 60 compared to 15.8% at day 14 after bleomycin 
treatment (Fig. 23B). Immunofluorescence for collagen revealed the absence of 
collagen at day 60 compared to day 14 after bleomycin treatment (Fig. 23C,D). 
Furthermore, activated MYFs (day 14 after bleomycin treatment) and activated MYF 
descendants (day 60 after bleomycin treatment) were isolated by FACS and gene 
expression was analyzed by qPCR. The results showed a downregulation of Acta2 
(Fig. 23E) and a significant 4.1-fold upregulation of Adrp (Fig. 23F), confirming the 
histological observations. There was a trend towards increase (1.25-fold) in Pparg 
expression (a key regulator of lipogenesis and lipofibroblast formation), and a 1.75-
fold increase in Fgf10 expression (Fig. 23G,H). To support these observations, 
FACS-based quantification of the neutral lipid stain (LipidTOX) was performed (Fig. 
23I-K). The results showed an increase in the number of LipidTOX+ cells at day 60 
(7.7%) compared to day 14 (3.2%) after bleomycin treatment (Fig. 23L). The 
proportion of lineage-labeled tdTomato+ cells that were stained for LipidTOX was 
also increased at day 60 (13.3%) compared to day 14 (6.2%) after bleomycin 
treatment (Fig. 23M). 
Additionally, immunofluorescent staining for ADRP revealed that only 1.5% of 
ASMCs and VSMCs were ADRP+ in saline treated lungs (data not shown), indicating 
that under homeostatic conditions, SMCs and LIFs are distinct mesenchymal 
lineages. At day 14 after bleomycin treatment a considerable proportion of lineage-
labeled activated MYFs were ADRP+ and LipidTOX+, indicating that LIFs might 
contribute to the accumulation of activated MYFs during fibrosis progression. 
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Figure 23: Activated MYFs acquire lipofibroblasts characteristics during 
fibrosis resolution. (A) Immunofluorescence for ADRP and SFTPC in lungs at day 
60 after bleomycin treatment. TdTomato, ADRP and SFTPC single channels are 
shown in addition to merge/DAPI image. The arrow points an ADRP+tdTomato+ cell 
adjacent to SFTPC+ cell (asterisk). (B) Quantification of the immunofluorescence 
showing increase in ADRP expression in labeled cells at day 60 compared to day 14. 
(C,D) Immunofluorescence for Collagen type I at day 14 and 60 after bleomycin 
treatment. (E-H) qPCR for Acta2, Adrp, Pparg and Fgf10 on labeled cells sorted from 
bleomycin treated lung at day 14 and 60 after treatment. (I-K) Gating strategy for 
FACS-based quantification of LipidTOX+ and tdTomato+ cell populations. (L-M) 
FACS-based quantification of LipidTOX+ and tdTomato+ cell populations in lung 
suspensions at day 14 and 60 after bleomycin treatment. BLM – bleomycin, FSC – 
forward scatter. N = 3-4 for BLM d14, N = 2-4 for BLM d60. Scale bar: 10 μm in A, 50 
μm in C,D. *P<0.05, *** P<0.001. (El Agha et al., 2017) 
 
4.2.4. Activated MYFs do not proliferate at peak of fibrosis and do not undergo 
apoptosis in fibrosis resolution 
In order to investigate whether activated MYFs proliferate at day 14 after bleomycin 
treatment immunofluorescence for Ki67 was performed. There was no co-localization 
of lineage-traced tdTomato+ cells and Ki67 staining observed, indicating that labeled 
activated MYFs do not proliferate (Fig. 24A-H). 
To test whether activated MYF descendants undergo apoptosis at day 60 after 
bleomycin treatment TUNEL staining was carried out. There was no sign of co-
localization observed between lineage-labeled tdTomato+ activated MYF 
descendants and TUNEL+ cells indicating the absence of apoptosis in activated MYF 
descendants.  
 
 
 
Results 61 
 
Figure 24: Proliferation and apoptosis in labeled cells of bleomycin treated 
Acta2-CreERT2; tdTomatoflox mice at the peak of fibrosis and during resolution 
phase. (A-D) Immunofluorescence for Ki67 of bleomycin treated lungs at day 14 
after the treatment. Single channels DAPI, tdTomato and ACTA2 are shown in 
addition to merged image. Higher magnifications of images marked in boxes are 
shown in (E-H). White arrows point apoptotic cells. Note the absence of co-
localization between tdTomato+ and Ki67+ cells. (I-L) TUNEL staining of bleomycin 
treated lungs at day 60 after the treatment. White arrows point apoptotic cells. Note 
the absence of co-localization between tdTomato+ and TUNEL+ cells. BLM – 
bleomycin. N = 3 for BLM d14, N = 2 for BLM d60. Scale bars: 50 μm in A-D, 25 μm 
in E-L. (El Agha et al., 2017) 
 
 
 
Discussion 62 
5. Discussion 
 
5.1. Origin of pulmonary SMCs and alveolar MYFs  
 
Our detailed side-by-side analysis of various mesenchymal driver lines allowed 
labeling of mature SMCs and their progenitors. Using different driver lines the 
contribution of different mesenchymal lineages to SMC lineage was analyzed (Fig. 
25). The minor contributors are mesothelial and sub-mesothelial-mesenchymal 
lineages, represented by WT1+ and FGF10+ cells. These two lines also show low 
specificity towards the SMC lineage. The major contributors are the GLI1+ and 
AXIN2+ lineages that are enriched in the sub-epithelial mesenchyme, where they are 
targets of epithelium-derived growth factors such as SHH and various WNT ligands. 
Nevertheless, the GLI1+ and AXIN2+ lineages also show low specificity towards the 
SMC lineage during embryonic development. However, the GLI1+ lineage shows 
both high contribution and high specificity to the SMC lineage during the alveolar 
stage of postnatal lung development. In particular, our results confirm the previous 
finding that this driver line is useful to target alveolar MYFs at this stage (Li et al., 
2015). 
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Figure 25: Model summarizing the impact of different progenitor populations 
on the SMC lineage. Mesothelial WT1+ and FGF10+ cells that can be labeled using 
Wt1CreERT2, Fgf10CreERT2 contribute in a minor way to the SMC lineage, while GLI1+ 
and AXIN2+ cells that can be labeled using Gli1CreERT2 and Axin2CreERT2 contribute 
massively to the SMC lineage. Sub-mesoth. – sub-mesothelial, sub-epith. – sub-
epithelial. (Moiseenko et al., 2017, Stem Cells, manuscript accepted for publication) 
As expected, the Acta2-CreERT2 line showed high specificity to the ASMC and 
VSMC lineages. A single IP injection of tamoxifen at E15.5 led to 91±5% labeling of 
all SMCs in the lung at E18.5 (Fig. 13N,O). This line also allows labeling the absolute 
majority of SMCs in the adult lung (El Agha et al., 2017). One of the questions that 
we tried to answer was whether pre-existing ACTA2+ cells at early lung development 
serve as progenitors for future SMCs that progressively appear as the epithelial 
tubes undergo iterative branching. Our data revealed that E11.5 ACTA2+ cells and 
their descendants settled in the proximal regions of the lung at E18.5, whereas E15.5 
ACTA2+ cells and their descendants populated both the proximal and distal regions 
at E18.5. Therefore, we conclude that the Acta2-CreERT2 line mostly targets 
differentiated ASMCs and VSMCs, but not their progenitors. One of the novel 
findings of this work is that the Acta2-CreERT2 line also labels ACTA2low 
parenchymal cells at E18.5. In addition, we provide evidence that these cells are 
likely progenitors for ACTA2+ ELN+ alveolar MYFs that are located at the tips of 
secondary septa at PN14. No evidence for proliferation was observed in these cells 
at E18.5 or PN14 (Fig. 17). Moreover, when labeling at E15.5, we found similar 
numbers of tdTomato+ cells in the lung parenchyma at E18.5 and PN14, 
demonstrating limited expansion and lack of proliferation in these cells. These results 
confirm that ACTA2 is a marker for differentiated smooth muscle cells as previously 
described (Fatigati and Murphy, 1984; Owens et al., 2004) and also demonstrate that 
late progenitors/early differentiated alveolar MYFs are generally ACTA2low compared 
to bona fide SMCs. 
The presence of ACTA2low cells was also shown using 3D-reconstruction of a thick 
vibratome section of a wild type lung immunostained for ACTA2 (Fig. 26) The 
staining clearly showed the presence of ACTA2high cells that are located at ASMC 
and VSMC regions and also ACTA2low cells located in parenchyma. These ACTA2low 
cells are likely progenitors for alveolar MYFs. 
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Figure 26: ACTA2high and ACTA2low populations in the wild type lung. (A-B) 
Immunofluorescence for ACTA2 of the thick (100 μm) sections of CD1 mouse lungs. 
Higher magnification of image marked in box is shown in (B). Note that intensity of 
ACTA2-signal is much higher in airway and vascular SMCs than in parenchymal 
cells. N = 3. Scale bars: 75 μm in A, 15 μm in B. 
To analyze the gene array results, the “LungGENS” web tool was used. According to 
the “LungGENS” (Du et al., 2015), that compiles mRNA signatures of single cells 
isolated from the entire embryonic mouse lung at different stages, there are two 
types of fibroblasts observed at E18.5 – the Myofibroblast (MyoF) and the Matrix 
fibroblast (MFB). MyoFs were identified by the expression of genes involved in actin 
binding and smooth muscle contraction, and the signature genes included hedgehog-
interacting protein (Hhip), Acta2, gamma 2 smooth muscle actin (Actg2), myosin 
heavy polypeptide 11 (Myh11) and transgelin (Tagln). MFBs express genes 
associated with extracellular matrix and cell adhesion, and the signature genes 
included fibronectin (Fn1), Eln, vascular cell adhesion molecule (Vcam) and Fgf10. 
Another powerful characteristic of LungGENS is that the expression level of a given 
gene can be assessed and compared among different cell types. We found that in 
our conditions, alveolar MYF progenitors resemble the MFB group, but with higher 
specificity - most of the signature genes for the MFB were even more enriched in 
alveolar MYF progenitors vs. SMCs. For example, Eln expression in MFBs is around 
2.5 fold higher than in MyoFs (375 vs. 139), which is quite surprising for a gene that 
appears to be expressed specifically in alveolar MYFs. In our case, it was 400 fold 
higher in alveolar MYF progenitors than in SMCs according to qPCR data (Fig. 15B). 
Pdgfra is upregulated by 7 fold in MyoFs compared to MFBs (102 vs.15), while 
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according to our data, this gene was upregulated by 70 fold according to qPCR 
analysis and 93 fold according to gene arrays in alveolar MYF progenitors compared 
to SMCs. SMCs in our conditions resemble MyoF from LungGENS.  Interestingly, 
some feature genes of MyoF, for example Hhip, were highly upregulated in alveolar 
MYF progenitors. This suggests that the cell type called “MyoF” in LungGENS likely 
contains different subpopulations, such as SMCs and alveolar MYF progenitors. 
These results underscore the difficulty to assign specific cell types to a given 
transcriptomic signature obtained from single cell experiments, especially when the 
single cell data were obtained by systematically analyzing all the cells, without 
introducing a specific filter such as lineage-labeled cells. In the future, single-cell 
transcriptomics with the Acta2-CreERT2 line will be a powerful tool to distinguish 
between the different subpopulations of SMCs. 
The role of SHH in the formation of SMCs has already been proposed. SHH 
knockout lungs fail to undergo normal branching morphogenesis (Pepicelli et al., 
1998). Importantly, ACTA2+ cells are completely absent in SHH knockout lungs. 
ACTA2+ alveolar MYFs play a key role in alveolar formation. Interruption of 
alveologenesis is a hallmark of diseases like BPD in premature born infants and 
COPD in adult lungs. Both alveolar defects lead to high morbidity and mortality. 
Hyperoxia-induced lung injury, a model of BPD, causes up-regulation of SHH and it’s 
downstream target PTCH1 and thickening of alveolar walls (Dang et al., 2012), 
suggesting that SHH play a role in postnatal lung pathology. A recent study has 
shown that GLI1+ cells labeled at E10.5 give rise to alveolar MYFs at PN14 (Li et al., 
2015). In our experimental conditions, we observed that HH activation also marks 
alveolar MYF progenitors, postnatally. The observation that the Gli1CreERT2 driver 
allows labeling more alveolar MYFs at PN14 when labeled between PN2-PN14 
rather than between PN2-PN5, suggests that not all the alveolar MYF progenitors are 
GLI1+ at PN2-PN5. There is likely another pool of progenitors that gradually acquires 
Gli1 expression later during alveologenesis. The data suggest that there is a 
progressive increase in hedgehog signaling as alveologenesis proceeds, and this 
correlates with increased alveolar MYFs formation. Interestingly, it has been shown 
that Shh is expressed much higher at E14.5 in comparison to E18.5 (Li et al., 2015). 
That means that there might be at least two time periods during lung development 
when SHH is activated – first during early lung development between E10.5-E14.5 
and second postnatally during the onset of alveolarization at P0 till peak of 
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alveolarization P15 and is undetectable at P24 (end of alveolarization) (Miller et al., 
2001). 
WNT signaling is also involved in SMC formation during embryonic development. It 
plays a critical role in proliferation, migration and differentiation of SMC progenitor 
cells (Cohen et al., 2009; Kumar et al., 2014; Mailleux et al., 2005). In our study, 
overall WNT signaling was activated in alveolar MYF progenitors but not in 
differentiated SMCs. This again underlines the importance of WNT signaling for 
ACTA2+ precursors, but not mature SMCs. It would be interesting to find the status of 
WNT signaling in mature differentiated ACTA2+ MYF. Axin2 was also upregulated in 
alveolar MYF progenitors, but not in SMCs. AXIN2+ cells, labeled at E11.5, 
contributed to the ASMC and VSMC lineages. In differentiated SMCs, Axin2 
expression appears downregulated, suggesting downregulation of WNT signaling in 
differentiated vs. progenitor SMC. Wnt5a was one of the highest upregulated genes 
in alveolar MYF progenitors. It has already been shown that deletion of Wnt5a leads 
to increased proliferation of the mesenchyme and dysregulated lung maturation (Li et 
al., 2002). In the lungs of asthma and COPD patients, WNT5A, activated by TGFβ-
signaling, promotes excessive SMC proliferation (Kumawat et al., 2013). Recently, it 
has been shown that in the lungs of COPD patients up-regulated Wnt5a attenuated 
alveolar epithelial cell wound healing and transdifferentiation. Overexpression of 
Wnt5a exacerbated airspace enlargement and inhibition of Wnt5a improved lung 
function and attenuated lung tissue destruction (Baarsma et al., 2017).  
Using the Acta2-CreERT2 line, we found that in addition to WNT and SHH signaling 
pathways, FGF signaling was also activated at E18.5 in alveolar MYF progenitors 
compared to SMCs. FGF signaling, particularly FGF10, is known to be important for 
alveolar MYF formation, and Fgf10 hypomorphic lungs are characterized by the 
absence of alveolar MYFs (Ramasamy et al., 2007). Interestingly, alveolar MYFs 
have never been described as a potential source of FGF10 in the developing lung. 
In the future, it will be important to analyze the transcriptome of ACTA2+ cells labeled 
at E15.5 and examined at E18.5, PN14, PN30 and PN60. This approach should 
enable the identification of the genes and pathways important for alveolar MYF 
differentiation and dedifferentiation. 
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5.2. Origin and fate of activated MYFs in bleomycin-induced lung 
fibrosis  
 
Currently there are only few treatments against IPF. The IPF patients are mostly at 
the end stage of fibrosis when being diagnosed, making the investigation of the 
mechanisms underlying the onset of disease and tissue remodeling difficult. Using 
mouse models of lung fibrosis, it is possible to understand better the processes of the 
initial formation of lung fibrosis, for example to identify possible sources of activated 
MYFs in IPF; as well as further investigate the resolution phase. 
The main feature of IPF is the accumulation of ECM-secreting activated 
myofibroblasts, that accumulate in fibrotic regions and lead to tissue scarring. For a 
long time researchers have been trying to identify the cell types that give rise to 
activated MYFs in order to interfere with the process of their formation. 
The hypothesis that activated MYFs can originate from pre-existing SMCs was based 
on a study where remodeled excessive VSMCs in hypoxia model of pulmonary 
hypertension (PH) in mice originated from pre-existing SMCs (Sheikh et al., 2014). 
However in our work lineage-labeled pre-existing SMCs were not found in the fibrotic 
areas and did not contribute to fibrosis. Thus, activated MYFs in lung fibrosis do not 
originate from pre-existing SMCs and rather have other ACTA2- sources.  
One of the potential source for activated MYFs are Gli1+ cells, since SHH has been 
shown to be involved in TGF-β1-induced MYF differentiation (Cigna et al., 2012) and 
Gli1+ cells were already shown to give rise to activated MYFs (Kramann et al., 2015). 
In our work we also demonstrate that GLI1+ cells give rise to different ACTA2+ cell 
populations. Using Gli1CreERT2 line to target GLI1+ cells would be a good 
instrumental approach to investigate the differentiation and de-differentiation of 
activated MYFs in bleomycin-induced lung fibrosis from the angle of SHH signaling.  
The great advantage of bleomycin-induced mouse model of lung fibrosis is that 
fibrosis is reversible; mice recover completely, thus giving the opportunity to study 
regeneration process. Using this reversibility of fibrosis in mice, we aimed to 
investigate the fate of activated MYFs after fibrosis resolution. One of the observation 
of our work was that activated MYFs and their descendants are not cleared from the 
lung, they do not undergo apoptosis and do not disappear, they are still present in 
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the lung at day 60 after bleomycin injury, when fibrosis is resolved. These findings 
agree with previously published reports that activated MYFs are not cleared from the 
tissue during fibrosis resolution but rather de-differentiate (Kosla et al., 2013; Reddy 
et al., 2014). The de-differentiation of activated MYFs was also proposed in the study 
where it was shown that differentiation of MYFs is regulated by TGF-β1/ALK5/ MyoD 
and suppression and de-differentiation of MYFs is driven by mitogens/ERK-
MAPK/CDKs (Hecker et al., 2011). Our gene arrays on sorted lineage-traced 
tdTomato+ cells show no significant upregulation of apoptotic markers at day 60 
compared to day 14 after bleomycin administration (1.2, 1.6 and 1.3-fold 
downregulation of caspase 3 (Casp3), Casp6 and Casp7 respectively at day 60 
compared to day 14). No apoptosis in activated MYF descendants at day 60 after 
bleomycin injury was observed in TUNEL staining of lung sections (Fig. 24).  
Another observation was that a subset of these labeled activated MYFs undergoes 
transition to lipofibroblast-like phenotype after fibrosis resolution. LIFs are lipid-
droplet-containing cells that take part in surfactant production by AECII and has been 
also shown to support AECII clonogenic growth in vitro (Barkauskas et al., 2013; 
Schultz et al., 2002). LIFs also contain retinoic acids that have been shown to be 
important for the alveolar septation postnatally (Simon and Mariani, 2007). During 
late lung development LIFs can be detected in rat lung starting from E16 increasing 
in number with the peak on the second postnatal week, when alveolarization is at it’s 
peak (Tordet et al., 1981). PPAR pathway that is required for the maintenance of the 
LIF phenotype, is downstream of parathyroid hormone-related protein (Pthrp) 
signaling (Torday et al., 2003). It has been demonstrated that inactivation of the 
Pthrp pathway in vivo results in abnormal alveolarization and surfactant synthesis 
(Rubin et al., 2004). This suggests that LIFs are involved in alveologenesis and 
septation. During fibrosis resolution the damaged tissues undergo the so-called “de-
novo” alveologenesis, where LIFs may play the same important role as during 
development. This can partly explain the de-differentiation of activated MYF to LIF 
program.  
The transdifferentiation of cells from contractile SMC-like phenotype to adipocyte-like 
phenotype has already been shown by other investigators. Lipid accumulation in 
skeletal muscles has been reported in Dysferlin-deficient mice (Grounds et al., 2014). 
Under special culture conditions, permissive for adipogenesis, skeletal muscle can 
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transdifferentiate to mature adipocytes via PPAR pathway activation and 
upregulation of lipogenic markers Pparg and C/ebpa (Hu et al., 1995).  Our gene 
arrays result showed activation of PPARγ signaling pathways in activated MYF 
descendants at day 60 after bleomycin injury compared to activated MYFs at day 14, 
indicating that this pathway is involved in the reversal of activated MYFs phenotype 
to LIF-like phenotype, activating the genes involved in lipogenesis, cholesterol 
metabolism and adipocyte differentiation (Fig. 27). 
PPARγ is the major pathway that orchestrates lipogenic differentiation in adipocyte 
progenitors (preadipocytes) as well as LIF formation (Rehan and Torday, 2012). 
Additionally, PPARγ agonists were shown to be protective against fibrosis in mice 
(Fang et al., 2012; Genovese et al., 2005). A direct transcriptional target for PPARγ 
adiponectin showed a similar effect in primary culture of skin fibroblasts isolated from 
scleroderma patients (Fang et al., 2012). The potential use of PPARγ agonists to 
induce lipogenic differentiation in IPF would be a next important step to investigate.  
Interestingly, there have been controversial opinions about whether lipid-containing 
cells exist in the human lung. A recent study claimed the absence of these cells in 
the lung (Tahedl et al., 2014), however another study using Oil Red O staining 
showed that these cells exist in both infant and adult human lungs (Rehan et al., 
2006). The discrepancy between the findings can be related to the differences in 
detection methods (Ahlbrecht and McGowan, 2014).  
Although dedifferentiation of MYFs is happening in mouse model of lung fibrosis, this 
process is not studied in human IPF lungs. It is not yet known whether activated 
MYFs can dedifferentiate to cell types other than LIFs, this has to be investigated. 
Generally there is lack of knowledge regarding cellular heterogeneity of human lung 
mesenchyme. Better understanding of the human mesenchymal cell types and 
identifying new fibroblastic populations can give rise to new opportunities for IPF 
treatment.  
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Figure 27: Analysis of PPARγ signaling pathway on lineage labeled cells 
isolated from Acta2-CreERT2; tdTomatoflox mice during peak of fibrosis and 
resolution phase. Gene array analysis performed on sorted tdTomato+ cells 
showing activation of the PPARγ pathway in activated MYF descendants during 
fibrosis resolution. Green indicates upregulation in BLM d60 group. BLM – 
bleomycin. N = 3 for BLM d14, N = 2 for BLM d60. (El Agha et al., 2017)
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6. Conclusion 
 
The study overall gives more insight into the mechanisms underlying ACTA2+ 
precursor cells behavior and differentiation as well as offers extensive 
characterization of mature ACTA2+ cells during lung development and lung injury. 
In the first part of the study different progenitor lines were analyzed for their 
contribution to SMCs lineage. The major contributors were identified – GLI1+ and 
AXIN2+ cells give rise to majority of SMCs and alveolar MYFs in the embryonic lung, 
but these progenitor cells are not specific for only SMC lineage, they give rise to 
other mesenchymal cell types. Using Acta2-CreERT2 FACS-based isolation of 
lineage-traced cells followed by gene arrays, we identified transcriptomic signatures 
for alveolar MYF progenitors versus ASMCs and VSMCs. This new knowledge will 
allow in the future discriminating between the different subpopulations of ACTA2+ 
cells. Taken together, our results provide a more balanced view on the origin of the 
SMCs during embryonic lung development. Our side-by-side driver line analyses will 
be instrumental to design new experiments addressing the function of signaling 
pathways in various SMC and SMC-like subpopulations. 
The second part of this study gives better understanding of the origin and fate of 
activated MYFs in lung fibrosis. It was shown that activated MYFs do not originate 
from pre-existing ACTA2+ cells. In fibrosis resolution a phenotypic switch has been 
observed – activated MYFs acquire lipogenic program and become LIFs, and that 
process is dependent on PPARγ signaling. In future, PPARγ agonists should be 
considered as a potential treatment for IPF patients to switch myogenic phenotype in 
activated MYFs to lipogenic and induce fibrosis resolution. 
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7. Summary  
 
Alpha smooth muscle actin (ACTA2)-expression identifies pulmonary airway and 
vascular SMCs as well as alveolar myofibroblasts (MYFs). These cells are important 
for normal respiratory function and their dysregulation is associated with disease. 
Mesenchymal progenitors expressing fibroblast growth factor 10 (Fgf10), Wilm’s 
tumor 1 (Wt1) or glioma-associated oncogene 1 (Gli1) contribute to SMC formation 
from early stages of lung development. However, their respective contribution and 
specificity to the SMC and alveolar MYF lineages remain controversial. In addition, 
the contribution of mesenchymal cells undergoing WNT signaling remains unknown. 
Using Fgf10CreERT2, Wt1CreERT2, Gli1CreERT2 and Axin2CreERT2 inducible driver lines in 
combination with a tdTomatoflox reporter line, the respective differentiation of each 
pool of labeled progenitor cells along the SMC and alveolar MYF lineages was 
quantified. The results revealed that while FGF10+ and WT1+ cells showed a minor 
contribution to the SMC lineage, GLI1+ and AXIN2+ cells significantly contributed to 
both the SMC and alveolar MYF lineages, but with very limited specificity. Lineage 
tracing using the Acta2-CreERT2 transgenic line showed that differentiated airway 
and vascular SMCs labeled at E11.5 do not expand significantly to give rise to new 
SMCs at E18.5. However, ACTA2+ cells from E15.5 label almost all SMCs in the lung 
at E18.5, as well as alveolar MYF progenitors in the lung parenchyma. FACS-based 
isolation of different subpopulations of ACTA2+ lineage-traced cells followed by gene 
arrays, identified transcriptomic signatures for alveolar MYF progenitors versus 
airway and vascular SMCs at E18.5. Our results establish a new transcriptional 
landscape for further experiments addressing the function of signaling pathways in 
the formation of different subpopulations of ACTA2+ cells. 
Contractile ACTA2+ cells called activated myofibroblasts (MYFs) are the main 
effector cells in idiopathic pulmonary fibrosis (IPF). IPF is characterized by excessive 
accumulation of activated MYFs and lung tissue scarring. Currently there is no 
effective treatment against IPF. Understanding the origin of the activated MYFs is of 
great interest. Using Acta2-CreERT2 transgenic line to label pre-existing ACTA2+ 
showed that pre-existing ACTA2+ airway and vascular SMCs do not give rise to 
activated MYF. During resolution of fibrosis, we show that activated MYFs lose 
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ACTA2 expression and acquire lipofibroblast-like phenotype. Manipulating this 
phenotypic switch might offer new therapeutic opportunities for IPF patients.
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8. Zusammenfassung 
 
Glatte Muskelzellen der Atemwege und Blutgefäße der Lunge sowie 
Alveolarmyofibroblasten (MYFs) exprimieren Alpha-smooth-muscle-actin (ACTA2). 
Diese Zellen sind für die normale respiratorische Funktion von wichtiger Bedeutung, 
weswegen ihre Dysfunktion mit Erkrankungen assoziiert sind. Mesenchymale 
Progenitorzellen, die Fibroblastenwachstumsfaktor 10 (Fgf10), Wilm´s tumor 1 (Wt1) 
oder Glioma-assoziiertes Onkogen 1 (Gli1) exprimieren, sind an der Bildung von 
glatten Muskelzellen ab den frühen Stadien der Lungenentwicklung beteiligt. 
Allerdings ist diesbezüglich die Spezifität der Progenitorzellen und ihre anteilige 
Beteiligung an der Bildung der glatten Muskelzelllinien und der 
Alveolarmyofibroblastenzelllinie noch kontrovers. Weiterhin ist es ungeklärt, ob 
mesenchymale Zellen mit Einwirkung der WNT Signalwege an der Bildung der 
glatten Muskelzellen und der Alveolarmyofibroblasten beteiligt sind. Mit Hilfe der 
induzierbaren Driver-Mauslinien Fgf10CreERT2, Wt1CreERT2, Gli1CreERT2 und Axin2CreERT2 
in Kombination mit der Reporter-Mauslinie tdTomatoflox wurde die Differenzierung 
der entsprechend markierten Progenitorzellpopulationen zu den glatten 
Muskelzelllinien und Alveolarmyofibroblastenzelllinie quantifiziert. Die Ergebnisse 
zeigten, dass FGF10+ und WT1+ Zellen nur geringfügig an der Bildung der glatten 
Muskelzelllinie beteiligt sind, während GLI1+ und AXIN2+ Zellen signifikant, jedoch 
mit einer niedrigen Spezifität, zur Bildung sowohl der glatten Muskelzelllinien als 
auch der Alveolarmyofibroblastenzelllinie beitragen. Eine zeitliche Verfolgung der 
Zelldifferenzierung (lineage tracing) mit Hilfe der Acta2-CreERT2 transgenen 
Mauslinie ergab, dass an E11.5 markierte differenzierte glatte Muskelzellen der 
Atemwege und Blutgefäße nicht signifikant zur Bildung neuer glatter Muskelzellen an 
E18.5 beitragen. Andererseits sind an E15.5 ACTA2+ Zellen an der Bildung von 
nahezu allen glatten Muskelzellen und Progenitorzellen der Alveolarmyofibroblasten 
im Lungenparenchym an E18.5 beteiligt. Mittels einer FACS-basierten Isolation der 
verschiedenen ACTA2+ Subpopulationen mit anschließender Genarray-Analyse, 
identifizierten wir an E18.5 die Signaturen der Transkription für Progenitorzellen der 
Alveolarmyofibroblasten sowie für glatte Muskelzellen der Atemwege und Blutgefäße 
der Lunge. Unsere Ergebnisse etabliert eine neue Basis auf der Ebene der 
Transkription, um weitere Experimente zum Verständnis der Funktion der 
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verschiedenen Signalwege in der Bildung unterschiedlicher Subpopulationen 
ACTA2+ Zellen darauf aufzubauen.  
Als aktivierte Myofibroblasten (MYFs) genannte, kontraktile ACTA2+ Zellen, sind die 
hauptsächlichen krankheits-assoziierten Zellen bei der idiopathischen Lungenfibrose 
(IPF). Die IPF ist durch exzessive Akkumulation von aktivierten Myofibroblasten und 
Vernarbung des Lungengewebes charakterisiert. Aktuell besteht keine kausale 
Therapie für die IPF. Das Verständnis über die Herkunft der aktivierten 
Myofibroblasten ist somit von größtem Interesse. Mit Hilfe der Acta2-CreERT2 
transgenen Mauslinie markierte prä-existente ACTA2+ glatte Muskelzellen der 
Atemwege und Blutgefäße der Lunge zeigten, dass diese sich nicht zu aktivierten 
Myofibroblasten entwickeln. Während der Rückbildung der Fibrose, stellten wir fest, 
dass aktivierte Myofibroblasten ACTA2 Expression verlieren und einen 
Lipofibroblasten ähnlichen Phänotyp annehmen. Die Manipulation dieser 
phänotypischen Umwandlung stellt eine potentiell neue therapeutische Möglichkeit 
für Patienten mit IPF dar. 
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10. Supplementary material 
 
 
 
Supplementary Figure 1: Lack of leakiness in the mouse lines used. (A, C, E, G, 
I, K, M, O) Whole-mount images of the lungs in the presence or absence of 
tamoxifen induction. (B, D, F, H, J, L, N, P) Corresponding lung sections stained with 
DAPI. Note the absence of tdTomato signal in lungs that were not treated with 
tamoxifen. N = 3. Scale bar: 2.5 mm in E, G, I, M; 1.5 mm in K, O; 600 μm in C; 500 
μm in A; 200 μm in B, D, F, H, L, N, P; 100 μm in J. (Moiseenko et al., 2017, Stem 
Cells, manuscript resubmitted) 
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Supplementary Figure 2: Gating strategy for flow cytometry experiments. Initial 
gating for flow cytometry analysis of E18.5 Gli1CreERT2; tdTomatoflox lungs labeled at 
E11.5. Live cells were selected based on forward/side scatter profiles. SSC – side 
scatter, FSC – forward scatter. N = 3. (Moiseenko et al., 2017, Stem Cells, 
manuscript resubmitted) 
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Supplementary Table 1: Transcriptomic signatures enriched in alveolar MYF 
progenitors vs. ASMCs and VSMCs. 
 
Genes enriched in alveolar myofibroblasts 
Gpr64 (G protein-coupled receptor 64) FC=541.19, p<0.001 
Col6a4 (collagen, type VI, alpha 4) FC=352.14, p<0.001 
Wif1 (Wnt inhibitory factor 1) FC=235.57, p<0.0001 
Nrxn3 (neurexin III) FC=216.77, p<0.001 
Egfem1 (EGF-like and EMI domain containing 1) FC=209.38, p<0.0001 
Pcdh20 (protocadherin 20) FC=156.5, p<0.001 
Cyp2e1 (cytochrome P450, family 2, subfamily e, polypeptide 1) FC=114.56, 
p<0.0001 
Penk (preproenkephalin) FC=100.43, p<0.0001 
Pdgfra (platelet derived growth factor receptor, alpha polypeptide) FC=93.05, 
p<0.0001 
Greb1 (gene regulated by estrogen in breast cancer protein) FC=81.57, p<0.0001 
Col22a1 (collagen, type XXII, alpha 1) FC=76.11, p<0.0001 
Ccdc3 (coiled-coil domain containing 3) FC=73.52, p<0.0001 
Esr1 (estrogen receptor 1 (alpha)) FC=65.34, p<0.0001 
Fmo4 (flavin containing monooxygenase 4) FC=64, p<0.0001 
Adgrl3 (adhesion G protein-coupled receptor L3) FC=61.82, p<0.0001 
Mkx (mohawk homeobox) FC=56.88, p<0.01 
Zfp536 (zinc finger protein 536) FC=54.95, p<0.0001 
Gria3 (glutamate receptor, ionotropic, AMPA3 (alpha 3) FC=53.82, p<0.0001 
Dnm3os (dynamin 3, opposite strand) FC=52.34, p<0.0001 
Scara5 (scavenger receptor class A, member 5 (putative)) FC=52.34, p<0.0001 
Lgr5 (leucine rich repeat containing G protein coupled receptor 5) FC=51.62, 
p<0.0001 
Aldh1a3 (aldehyde dehydrogenase family 1, subfamily A3) FC=49.52, p<0.001 
Lamc3 (laminin gamma 3) FC=49.52, p<0.0001 
Rerg (RAS-like, estrogen-regulated, growth-inhibitor) FC=47.18, p<0.01 
Slc28a3 (solute carrier family 28 (sodium-coupled nucleoside transporter), member 
3) FC=44.32, p<0.001 
Supplementary material 91 
Kiss1 (KiSS-1 metastasis-suppressor) FC=41.07, p<0.0001 
Fmo2 (flavin containing monooxygenase 2) FC=37.53, p<0.0001 
Enpp2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) FC=37.27, p<0.0001 
Snai1 (snail family zinc finger 1) FC=35.5, p<0.0001 
Frem1 (Fras1 related extracellular matrix protein 1)  FC=33.82, p<0.0001 
Lef1 (lymphoid enhancer binding factor 1) FC=32, p<0.0001 
Gdf10 (growth differentiation factor 10) FC=32, p<0.0001 
Cacna1e (calcium channel, voltage-dependent, R type, alpha 1E subunit) 
FC=29.65, p<0.01 
Tcf7 (transcription factor 7, T cell specific) FC=26.54, p<0.0001 
Trim67 (tripartite motif-containing 67) FC=26.54, p<0.0001 
Reck (reversion-inducing-cysteine-rich protein with kazal motifs) FC=26.17, 
p<0.0001 
Vstm2b (V-set and transmembrane domain containing 2B) FC=25.99, p<0.001 
Adamts14 (a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 14) FC=25.11, p<0.0001 
Agt (angiotensinogen (serpin peptidase inhibitor, clade A, member 8)) FC=24.76, 
p<0.01 
Glrp1 (glutamine repeat protein 1) FC=22.78, p<0.01 
Negr1 (neuronal growth regulator 1) FC=21.11, p<0.01 
Foxf2 (forkhead box F2) FC=20.82, p<0.0001 
Jph1 (junctophilin 1) FC=18.89, p<0.05 
Slco1a4 (solute carrier organic anion transporter family, member 1a4) FC=18.51, 
p<0.001 
Mmp2  (matrix metallopeptidase 2) FC=18.25, p<0.0001 
Entpd1 (ectonucleoside triphosphate diphosphohydrolase 1) FC=16.11, 
p<0.0001 
Sncaip (synuclein, alpha interacting protein (synphilin)) FC=15.56, p<0.0001 
Kcns3 (potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3) 
FC=14.82, p<0.001 
Zfp385b (zinc finger protein 385B) FC=14.22, p<0.01 
Igfbp3 (insulin-like growth factor binding protein 3) FC=12.55, p<0.001 
Megf10 (multiple EGF-like-domains 10) FC=12.38, p<0.01 
Pappa2 (pappalysin 2) FC=11.79, p<0.0001 
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Fndc1 (fibronectin type III domain containing 1) FC=11.71, p<0.001 
Wnt5a (wingless-type MMTV integration site family, member 5A) FC=11.48, 
p<0.0001 
Megf10 (multiple EGF-like-domains 10) FC=12.38, p<0.01 
Tgfbr3 (transforming growth factor, beta receptor III) FC=10.48, p<0.0001 
Cdh10 (cadherin 10) FC=9.99, p<0.001 
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Supplementary Table 2: Transcriptomic signatures enriched in ASMCs and 
VSMCs vs. alveolar MYF progenitors. 
 
Genes enriched in smooth muscle cells 
C1qc (complement component 1, q subcomponent, C chain) FC=439.58, p<0.0001 
Csrp3 (cysteine and glycine-rich protein 3) FC=424.61, p<0.0001 
Sln (sarcolipin) FC=296.11, p<0.0001 
Cox8b (cytochrome c oxidase subunit VIIIb) FC=203.66, p<0.0001 
Myl4 (myosin, light polypeptide 4) FC=198.09, p<0.0001 
Actn2 (actinin alpha 2) FC=178.53, p<0.0001 
Chrm2 (cholinergic receptor, muscarinic 2, cardiac) FC=159.79, p<0.0001 
Hspb7 (heat shock protein family, member 7 (cardiovascular)) FC=134.37, 
p<0.0001 
Myl2 (myosin, light polypeptide 2, regulatory, cardiac, slow) FC=129.79, p<0.0001 
Ccl12 (chemokine (C-C motif) ligand 12) FC=116.97, p<0.0001 
Slc22a1 (solute carrier family 22 (organic cation transporter), member 1) 
FC=101.83, p<0.0001 
Cd163 (CD163 antigen) FC=82.71, p<0.0001 
Tmem182 (transmembrane protein 182) FC=58.89, p<0.0001 
Nkx2-5 (NK2 homeobox 5) FC=49.18, p<0.0001 
Ankrd1 (ankyrin repeat domain 1 (cardiac muscle)) FC=47.18, p<0.0001 
Nrap (nebulin-related anchoring protein) FC=39.4, p<0.0001 
Myl3 (myosin, light polypeptide 3) FC=37.79, p<0.0001 
Fabp3 (fatty acid binding protein 3, muscle and heart) FC=36.76, p<0.0001 
Ms4a6b (membrane-spanning 4-domains, subfamily A, member 6B) FC=33.13, 
p<0.0001 
Tcap (titin-cap) FC=32, p<0.0001 
Tbx20 (T-box 20) FC=28.64, p<0.0001 
Tenm2 (teneurin transmembrane protein 2) FC=20.53, p<0.0001 
Ldb3 (LIM domain binding 3) FC=19.56, p<0.001 
Hfe2 (hemochromatosis type 2 (juvenile) (human homolog)) FC=17.39, p<0.0001 
Klhl30 (kelch-like 30) FC=14.62, p<0.001  
Syn2 (synapsin II) FC=13.74, p<0.01 
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Tnnt3 (troponin T3, skeletal, fast) FC=11.88, p<0.001 
Dpf3 (D4, zinc and double PHD fingers, family 3) FC=11.55, p<0.001   
Habp2 (hyaluronic acid binding protein 2) FC=10.63, p<0.001 
